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INTRODUCTION 
 
 
1.1 Definition of absence epilepsy 
 
Epilepsies and epileptic syndromes describe complex disease states that are 
accompanied by abnormal hyper excitability and/or hyper synchronicity within the 
central nervous system (CNS). Epilepsy, as a disease entity, has first been mentioned by 
the ancient Egyptians who called it nesejet, or by the ancient Babylonians who called it 
the bennu disease (Temkin, 1994). 
About 500 BC, Hippocrates already claimed that the brain is the origin of epileptic 
seizure activity. Interestingly, however, this approach was consequently ignored over 
the millennia and there was hardly any substantial progress in understanding the 
etiopathogenesis of epilepsies till beginning of the modern times (Temkin, 1994). The 
clinical features of absence epilepsy itself were first described by Poupart in 1705 
(Temkin, 1994). Later on, Tissot described a girl with absences ―[…] avec un tres leger 
movement dans les yeux‖ and, in addition, repetitive generalized tonic–clonic seizures 
(GTCS) (Tissot, 1770). The term ―epileptic absence‖ was first introduced by Calmeil 
(1824); shortly thereafter, Esquirol (1838) raised the term petit mal in contrast to the 
generalized grand mal seizure group. Interestingly, Gowers (1881) gave a very detailed 
description of the absence seizures ―without conspicuous convulsions‖ and Friedmann 
(1906) first reported a long-term favorable prognosis but originally believed that 
absences were not epileptic. Sauer (1916) was the first to describe an important subtype 
of typical absence epilepsy, i.e., pyknolepsy (pycnolepsia, pure petit mal or socalled 
Friedmann syndrome), which was later characterized in detail also by Adie (1924). The 
establishment and characterization of the electroencephalography by Hans Berger in the 
1920s enabled Gibbs and colleagues to unravel absence-specific ictal discharges in 
clinical EEG recordings (Gibbs and Gibbs, 1935). The petit mal triad of Lennox (1945), 
which was misused and misunderstood, was clarified by the Commission on 
Classification and Terminology of the International League Against Epilepsy (ILAE) 
with the differentiation of typical from atypical absences (Gastaut, 1970). Later on, 
several groups studied absence epilepsy in greater detail using video-EEG monitoring  
(Penry et al., 1975; Stefan, 1982). Panayiotopoulos and colleagues (1997) described 
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syndrome-related characterization of typical absence seizures with video-EEG analysis 
in detail. Etiopathogenetically, absence epilepsies represent a most fascinating disease 
group which is probably one of the most well-characterized seizure types in humans and 
animal models (Danober et al., 1998; Manning et al., 2003; Steriade, 2005; Llinas and 
Steriade, 2006; Khosravani and Zamponi, 2006). As will be outlined below, these 
detailed insights fostered the development of rather effective and specific 
pharmacological approaches to treat absence epilepsy in humans. 
 
1.2 Epidemiology of absence epilepsy 
 
Nowadays, the frequency, importance and sociocultural implications of epilepsy can 
hardly be overestimated. Manifest epilepsy affects around 0.5–1% of the population in 
Europe and North America, 5% of the population perceive a single seizure in their 
lifetime, and about 10–15% exhibit an increased seizure susceptibility (Forsgren et al., 
2005a,b; Pugliatti et al., 2007). In the US, the prevalence of epilepsy is 1.77 million 
(Victor and Ropper, 2001). Estimates of worldwide prevalence of epilepsy suggest 50 
million people being affected with strong differences in regional distribution. Epilepsy 
incidence is age dependent; 70% of the patients suffering from epilepsy are below 25 
years of age, with most of the seizures beginning during childhood and early 
adolescence. About 40% of epilepsies belong to the generalized grand mal seizure 
family and another 40% represent complex partial, i.e., limbic or psychomotor seizures 
(Matthes and Schneble, 1999). In contrast, absence epilepsy makes up approximately 
10% of the epilepsies and is often accompanied by other types of generalized seizures 
(Panayiotopoulos et al., 1995). Estimates of the annual incidence of childhood absence 
epilepsy (CAE), a prototype of pure petit mal in children aged 0–15 years, range from 
6.3/100000 (Olsson, 1988; Loiseau et al., 1990) to 8.0/100000 (Blom et al., 1978; 
Posner, 2006). The prevalence of CAE was estimated at 10% (Callenbach et al., 1998) 
and 12.1% (Berg et al., 1999) for children younger than 16 years. Further detailed 
information on current epidemiology is provided by Jallon and Latour (2005). 
Interestingly, CAE is two- to fivefold more frequent in females than in males (Posner, 
2006). Given the severe sociocultural implications, the necessity for efficient 
pharmacological treatment of absence epilepsies is self-evident (Manning et al., 2003; 
Rogawski and Loscher,2004). 
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1.3 Classification and clinical phenomenology of absence epilepsy 
 
1.3.1 Typical absence epilepsy 
 
Systematically, absence epilepsies can be differentiated into typical and atypical forms 
with typical absences being further categorized into simple and complex ones. 
According to the nomenclature proposed by the Commission on Classification and 
Terminology of the ILAE (Sirven, 2002), typical absence seizures can be found in the 
following epilepsy syndromes: 
 
a. Typical absence seizures are the archetype of childhood absence epilepsy (CAE, 
pycnolepsy, pycnoleptic petit mal, pure petit mal, Friedmann syndrome) 
(Panayiotopoulos, 1999; Panayiotopoulos, 2005b) with an age of onset of 2–8 years and 
a peak incidence of 5–7 years. There is an ongoing debate whether infantile forms of 
absence epilepsies with an onset from the 1st to the 4th year of age (early onset absence 
epilepsy, EOAE) should be separated from childhood absence epilepsy with an onset 
later on until the 12th year of onset. This debate ranks about different aetiologies, 
manifestation, semiology, treatment and courses compared to CAE in children over 4 
years of age. Patients generally display a normal neurological development and 
absences exhibit spontaneous remission (>90%) before puberty even without 
pharmacological treatment. CAE is the prototype of an idiopathic, age-related epileptic 
syndrome with characteristic ictal bilaterally synchronous, high-amplitude 2.5 to 4 Hz 
spike-wave discharge (SWD) activity, double to triple spike-waves and slow-waves and 
normal interictal background activity. Epileptiform SWD episodes are brief (4–20 s) 
and frequent (10 to 100/day) with abrupt onset and termination. Due to its 
etiopathogenesis, absences in CAE and other absence entities are accompanied by 
severe impairment or loss of consciousness. The eyes stare or move slowly and random 
eyelid blinking, usually not sustained, may occur. In addition, speech and other 
voluntary activity stop within the first 3 s of the discharge. However, automatisms are 
also frequent. The diagnosis of CAE is not probable if myoclonic jerks occur shortly 
before the active stage of the absences, if there are clonic jerks during the absences, if 
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there is no impairment of consciousness during the SWD activity or if there are multiple 
spikes and ictal discharge fragmentations.  
 
b. Juvenile absence epilepsy (JAE, spanioleptic or cycloleptic absence epilepsy) is an 
idiopathic generalized epilepsy (IGE), mainly characterized by typical absences that are 
similar to, but probably not as severe and frequent as CAE (Panayiotopoulos et al., 
1997; Panayiotopoulos, 2005a). Random and infrequent myoclonic jerks as well as 
infrequent GTCS occur in most of the patients. The predominant age of onset is 
between 10 and 16 years with a peak at 10 to 12 years. JAE normally persists in 
adulthood, but absences tend to become less severe with age. The ictal EEG exhibits 
generalized, spike or multiple spike and slow-waves at 2.5 to 4 Hz. Typical exclusion 
criteria for JAE are mild impairment of consciousness, brief ictal discharges (less than 4 
s), eyelid or perioral myoclonus and rhythmic limb jerking. Single or arrhythmic 
myoclonic jerks during the absence ictus are incompatible with JAE. Visual and other 
sensory precipitation of absences may also speak against the diagnosis of JAE as well. 
In rare cases however, absence episodes might be triggered by intermittent 
photostimulation in JAE patients who also display photosensibility. 
 
c. Juvenile myoclonic epilepsy (JME, impulsive petit mal, bilateral massive myoclonus, 
Herpin-Janz syndrome, Janz syndrome) is a genetically determined, common IGE. The 
prevalence of JME is 5% to 11% among adults and adolescent patients with other 
epilepsies, and both sexes are equally affected. JME is characterized by myoclonic jerks 
on awakening, GTCS and typical absences in more than one third of the patients. The 
seizures have an age related onset (12–25 years) with absences first appearing either in 
childhood or early adolescence, followed by myoclonic jerks and GTCS in the middle 
teens. Seizure-precipitating factors like sleep deprivation and fatigue, alcohol, 
photosensitivity, mental and psychological arousal are prominent. JME seizures 
probably persist life-long, although absences may become less severe with age. Jerks 
and GTCS commonly improve after the fourth decade of life. Typical absences are not 
the predominant type of absence in JME, and they are usually mild and not associated 
with automatisms or localized limb jerks. Furthermore, the absence related impairment 
of consciousness is often subtle. Generalized discharges of 3–6 Hz spike-waves have an 
unstable intradischarge frequency with fragmentations and multiple spikes. 
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d. Myoclonic absence epilepsy is a rare generalized absence epilepsy of uncertain 
classification with a typical age of onset of 6–8 years. It is characterized by severe 
bilateral rhythmical clonic jerks, often associated with tonic contractions.  
 
e. Eyelid myoclonia with absences (also called eyelid myoclonia and absences, Jeavons 
syndrome) is an IGE manifested with frequent, pycnoleptic-like seizures. Eyelid 
myoclonia consists of marked, rhythmic and fast jerks of the eyelids and is often 
associated with jerky upward deviation of the eyeballs and retropulsion of the head. The 
seizures are brief (3–6 s) and occur mainly after eye closure (eye closure sensitivity). 
Additionally and concomitantly, absence seizures occur. The onset is usually in early 
childhood at an age of 10–12 years. Interestingly, patients are highly photosensitive in 
childhood, but this declines with age. Infrequent GTCS are inevitable in the long term, 
and they are likely to occur after sleep deprivation, fatigue and alcohol indulgence. 
Myoclonic jerks of the limbs may emerge, but they are infrequent and random. Eyelid 
myoclonia with absences often turns out to be pharmacoresistant and to persist life-long. 
The ictal EEG manifestations mainly consist of generalized polyspikes and slowwaves 
at 3–6 Hz, although the latter are more likely to occur after eye closure in an illuminated 
room. Total darkness abolishes the abnormalities related to eye closure. 
Photoparoxysmal responses are recorded from all untreated young patients.  
 
In clinical routine, the neurological symptoms of typical absence epilepsy can strongly 
vary among patients (Stefan, 1982; Panayiotopoulos et al., 1997; Capovilla et al., 2001; 
Loiseau, 2002; Panayiotopoulos, 2005a). Often, patients display a typical, sudden onset 
of seizure with characteristic open, glassy and staring eyes, turning pale, dropping 
whatever is in their hand and quivering of the eyelids. Concomitant relaxation of facial 
muscle often results in a typical absent impression of the patient. The impairment of 
consciousness may be severe and thus a predominant clinical symptom but sometimes 
also moderate, mild or inconspicuous so that proper detection may require additional, 
special cognitive testing to determine the degree of mental arrest. For the duration of 
ictal activity, patients typically experience a congrade amnesia. In typical simple forms, 
mental arrest is often associated with other manifestations, such as hypolocomotion and 
actions such as speaking and writing will be interrupted with no impairment of static 
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functions, i.e., posture. The ceased actions will be immediately resumed after seizure 
termination. Based on the impairment of consciousness, the patient will usually be 
unresponsive when spoken to. The attacks as outlined above typically last from a few 
seconds to rarely half a minute and terminate as rapidly as they commenced. In less 
severe absences, the patient may not entirely stop his or her activities, although reaction 
time and speech may considerably slow down. In their mildest form, absences may even 
be inconspicuous to the patient and imperceptible to the observer, as disclosed on video-
EEG recordings with errors and delays during breath counting or other cognitive testing 
during hyperventilation. In contrast, typical ―complex‖ forms of absence seizures are 
often associated with more sophisticated behavioural exacerbations, such as 
automatisms. These can be de novo automatisms, e.g., oral automatisms or 
perseverative forms in which patients exhibit stereotype behaviour such as walking, 
swimming and writing. Automatisms are common in typical absences when 
consciousness is sufficiently impaired, and they are more likely to occur 4–6 s after 
onset. Furthermore, these automatisms are more or less coordinated, adapted, i.e., 
eupractic or dyspractic, involuntary movements that may be an unconscious 
continuation of the preservative automatisms, de novo automatisms or both. Perioral 
automatisms such as lip licking, smacking, swallowing, or mute speech movements are 
also very common. Scratching, fumbling with the clothes and other limb automatisms 
may also occur. Many of these symptoms of both simple and complex absences can 
occur in the same patient. Also, one can observe a characteristic falling back of the head 
or vermiform turning of the head and trunk which is typical for tonic retropulsive, 
versive and rotatory subtypes of typical complex absence epilepsy. Clonic and 
myoclonic absence epilepsy usually affects the facial muscle, sometimes also the upper 
limbs. During the absence itself, clonic motor manifestations, rhythmic or arrhythmic 
and singular or repetitive are particularly frequent at the onset and can be continuous. 
However, they may also occur at any other stage of the seizure; usually they present as 
jerking of the eyelids, eyebrows and eyeballs, together or independently, as well as 
random or repetitive eye closures. Fast eyelid flickering is probably the most common 
ictal clinical manifestation and may occur during brief generalized discharges without 
discernible impairment of consciousness. Myoclonia at the corner of the mouth and 
jerking of the jaw are less frequently observed. Myoclonic jerks of the head, body and 
limbs may be singular or rhythmical and repetitive, and they may be mild or violent. 
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Absences may also be tonic or atonic. In absence with atonic components, the 
diminution of the muscle tone is usual and may lead to drooping of the head and, 
occasionally, slumping of the trunk, dropping of the arms and relaxation of the grip. 
Rarely, tone is sufficiently diminished to cause falls. In absence with tonic components 
the tonic muscular contraction may affect the extensor or the flexor muscles 
symmetrically or asymmetrically. The head may be pulled backwards, i.e., retropulsion 
or to one side, and the trunk may arch. Occasionally, absence seizures can be associated 
with autonomic signs, so-called vegetative absence epilepsy, including dilatation or 
constriction of the pupils, i.e., miosis and mydriasis, a flush, sweating, hypersalivation, 
paleness, enuresis or encopresis. Mixed forms of these absence subtypes are the rule 
rather than the exception. Absences may be the only type of seizures, as in CAE, or may 
be mild and non-predominant, as in JME. Typical absences are fundamentally different 
and pharmacologically unique compared to any other type of seizures, which also 
results in different pharmacological treatment. Thus, AEDs effective in focal seizures 
may be deleterious for absence seizures. Finally, the clinical EEG manifestations of 
typical absences are, by definition, widespread and often not as classical as in their 
archetype, CAE. If untreated, these seizure events can occur several hundred times a 
day. This impedes the child's development, often dramatically, and hence, inadequately 
treated absences can have severe sociocultural and educational impact particularly in 
young children and bring them into dangerous situations, e.g., in traffic.  
 
1.3.2 Atypical absence seizures and absence seizures in other epilepsy syndromes  
 
Atypical forms of absence epilepsy are often part of or accompanied by a complex 
epilepsy syndrome, such as Lennox–Gastaut syndrome (about two thirds have atypical 
absences), atypical benign partial epilepsy/pseudo-Lennox–syndrome (about 70% with 
absences (Hahn et al., 2001) or Doose syndrome (about 60–80% with absences; 
myoclonic astatic epilepsy (Guerrini, 2005) and thus exhibit a highly differentiated 
behavioural and electroencephalographic phenotype, whereas simple absence seizure 
types display more stereotype characteristics. Atypical absences can be symptomatic, 
e.g., in case of tumour formation in the frontal lobe, tuberous sclerosis (Bourneville–
Pringle disease), Aicardi syndrome, Angelman syndrome and neurometabolic disorders. 
Atypical absences differ from typical absences in the several ways:  
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1. Atypical absences occur in the context of mainly severe symptomatic or cryptogenic 
epilepsies of children with learning difficulties, who also suffer from frequent seizures 
of other types such as atonic, tonic and myoclonic seizures.  
2. In atypical absences, onset and termination is not as abrupt as in typical absences and 
changes in muscle tone are more pronounced. In addition, seizure episodes are 
unusually long in duration, e.g., more than 30 s. 
3. The ictal EEG of atypical absence consists of slow (<2.5 Hz), spike-and-slow waves. 
The discharge is heterogeneous, often asymmetrical, and may include irregular spike-
wave and slow-wave complexes and other paroxysmal activity. The background 
interictal EEG is usually abnormal. It is noteworthy that absence epilepsies in general 
can exhibit status-like character. Most absence seizures can further be provoked by 
hyperventilation or photostimulation and in contrast can often be aborted by strong 
auditory or other sensory stimuli, as it is known from, e.g., simple-partial seizure types. 
Finally, absence seizures are more common in tired than in vigilant patients. 
 
1.3.3 Additional rare syndromes associated with typical absence seizures 
 
Apart from those absence seizure types outlined above, there are a few rare syndromes 
(Panayiotopoulos et al., 1997), which should be briefly mentioned here. Perioral 
myoclonia with absences is an IGE with onset in childhood or early adolescence. They 
are characterized by rhythmic myoclonus of the perioral facial or masticatory muscles 
during the absence, together with a variable impairment of consciousness. The absences 
are frequent and brief. 
This seizure type may often be resistant to medication, unremitting and possibly life-
long. Phantom absences denote typical absences that are mild and often inconspicuous 
to the patient and imperceptible to the observer. However, video-EEG recording, breath 
counting or other cognitive testing during hyperventilation with brief 3–4 Hz spike or 
multiple spike-wave and slow-wave discharges can be used in order to disclose the 
occurrence of such absences. The absences are simple, occasionally with eyelid 
blinking. Although they may be clinically unrecognized, they usually manifest in adult 
life with GTCS and often with absence status epilepticus (Panayiotopoulos et al., 1997). 
Reflex absences represent typical absences with specific modes of precipitation, e.g., 
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photic pattern, video games, thinking, reading, etc. (Panayiotopoulos, 2005b). 
Photosensitivity is estimated to occur in approximately 50% of patients with onset of 
absences in childhood or adolescence, and it is often associated with an unfavourable 
prognosis (Lu et al., 2008). The best-defined syndrome with photosensitivity is eyelid 
myoclonia and absences (Jeavons syndrome). Absences with single myoclonic jerks 
during the absence ictus are typical absences with single, often violent jerks of the head, 
body or limbs. They may appear in early childhood and continue in adult life—often 
with other types of generalized seizures. They are difficult to treat and may have a bad 
prognosis. Symptomatic and cryptogenic absences may be, as the name suggests, 
symptomatic, arising as a consequence of a known disorder of the central nervous 
system (Ferrie et al., 1995), or cryptogenic, i.e., resulting from a suspected, but 
unknown, cause. Symptomatic and cryptogenic absences may be focal or diffuse, 
traumatic, metabolic or inflammatory. 
 
1.4 Animal model of absence epilepsy 
 
Genetic rat model of absence epilepsy have been studied for many years and thought to 
mimic more accurately the spontaneous seizures of human epilepsy than do drug-
induced animal models (Coenen et al., 2003).  
GAERS (Genetic Absence Epilepsy Rats from Strasbourg) are a well-validated animal 
model of human Idiopathic Generalised Epilepsy (IGE), possessing a similar 
electrophysiological, ontogenic and pharmacological profile to the human condition 
(Danober et al., 1998). Historically, the GAERS colony was derived from Wistar rat and 
selectively bred for the seizure phenotype so that 100% of progeny spontaneously 
develop the epilepsy. A non-epileptic control (NEC) strain was also derived from the 
original colony by selectively breeding for the lack of seizure expression, providing a 
powerful control strain, since any differences between the two strains would have a high 
a priori chance of being aetiologically associated with the epilepsy. In addition to 
developing epilepsy, the GAERS strain also exhibits a range of behaviours indicative of 
affective disturbance, including increased anxiety and depressive like behaviours (Jones 
et al., 2008), intimating that this rat strain also models the well-documented mood 
disturbances observed in clinical IGE populations (Caplan et al., 1998, 2005; Davies et 
al., 2003; Jones et al., 2007; Ott et al., 2003; Tellez-Zenteno et al., 2007).  
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The rats strain named WAG/Rij (Wistar Albino Glaxo strain bread in Rijswijk) exhibits 
spontaneous SWDs  that have a frequency of 7 to 11 Hz, duration of 1 to 45 s and 
amplitude of 200 to 1000 µV (van Luijtelaar et al.,1986;  Coenen et al., 1987,1992). The 
spike-wave discharges become manifest in the cortical EEG at an age of 2 to 3 months, 
while at a younger age spike-wave discharges are not detectable. At an age of 6 months, 
both male and female rats show about 16–20 discharges per hour, with an average 
duration of about 5 s. This amounts to several hundred discharges per day (Coenen and 
van Luijtelaar, 1987). 
Characteristics in the behaviour of WAG/Rij rats have been studied extensively and are 
quite similar to those of outbred Wistar rats with which they have been compared. 
Typical features of WAG/Rij rats are a short latency to emerge from the home cage into 
familiar and novel environments; low open-field defecation and high open-field 
ambulation; a low apomorphine-induced gnawing score; a high running-wheel activity; 
nondistinctive sleep percentages; good two-way, active shock-avoidance acquisition; 
and only slightly deficient working, albeit normal reference, memory scores in two 
spatial memory tasks (de Bruin et al., 2001; Festing and Bender, 1984; Harrington, 
1972; van Luijtelaar and Coenen, 1988; van Luijtelaar et al., 1989).  
 
1.5 Theoretical considerations: classical concepts of absence Epilepsy 
 
The highly synchronous appearance of SWDs in both hemispheres led to the assumption 
by early researchers that SWDs could arise from a central structure with widespread 
cortical projections that could distribute paroxysmal activity over the entire cortex. They 
proposed the existence of a subcortical pacemaker for SWDs (Jasper and Kershman, 
1941). A few years later the ‗‗centrencephalic‘‘ concept was introduced (Penfield and 
Jasper, 1954). This ‗centrencephalic integrating system‘ was thought to be located in the 
brain stem and diencephalon. Moreover, this system was believed to be responsible for 
the bilateral onset of the SWDs and the loss of consciousness. Subsequent stimulation 
studies in cats gave rise to the hypothesis that SWDs are likely to originate from the 
non-specific part of the thalamus, the intralaminar nuclei, which project diffusely to 
many cortical regions. The role of these nuclei in the generation of SWDs in humans 
remained unclear, in part because comparative anatomical studies showed that the 
thalamus in mammals is less developed than in humans (Ajmone-Marsan, 1965; Pollen 
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et al., 1963) and depth intracranial recordings were not an option. Despite these 
drawbacks, the ‗‗centrencephalic‘‘ concept was gradually transformed into a ‗‗thalamic 
theory‘‘. Direct evidence of SWDs beginning in the thalamus with 1–2 s cortical delay 
was obtained in patients during absence seizures using simultaneous thalamic and 
cortical local field potentials (Williams, 1953). To date, the ‗‗thalamic theory‘‘ remains 
valid and well accepted and, furthermore, has received recent support from modern 
techniques like positron emission tomography and fMRI (Prevett et al., 1995; Salek-
Haddadi et al., 2003), although it can be questioned whether the temporal resolution of 
PET and fMRI is currently sufficient to establish temporal differences between cortical 
and subcortical regions. Using depth recordings in epileptic patients, Bancaud (1969, 
1972) observed that the spontaneous discharges occurring during spontaneous petit mal 
or grand mal seizures might initially be localized to the cerebral cortex, in the vicinity of 
an identified lesion, particularly in the frontal lobe. This and other observations did not 
fit into the centrencephalic theory (Petsche, 1962). Moreover, similar attacks could be 
reproduced by electrical stimulation of the same cortical epileptogenic zone (Bancaud et 
al., 1974). Therefore, it was suggested that generalized SWDs are secondary to a diffuse 
focal discharge in the frontal cortex. After their cortical onset, they are rapidly 
propagated throughout the whole cortex through various cortico-cortical pathways 
(Bancaud, 1971). In addition, the bilateral synchrony during typical SWDs was not as 
perfect as previously believed (Lüders et al., 1980). Niedermeyer (1996) presented a 
new ‗‗cortical theory‘‘: primary generalized epilepsy is the expression of cortical 
pathology; generalized SWDs are generated in the mesiofrontal cortex, from where they 
rapidly spread to other cortical areas. The thalamus certainly participates, but only 
‗‗plays second fiddle‘‘ in carrying out normal physiological thalamo-cortical 
interactions. The third theory combined thalamic and cortical processes for the initiation 
and maintenance of absence seizures. Gloor (1969) saw a role for the cortex in the 
production of these generalized discharges and proposed that a ‗‗cortico-reticular‘‘ 
mechanism was involved in their generation, using experimental data collected in the 
feline generalized penicillin absence epilepsy model (Gloor et al., 1990; Kostopoulos, 
2000). In this model, systemic injections of penicillin, a weak GABAA receptor 
antagonist, caused a gradual dose-dependent transformation of spindles into absence 
seizures. SWDs could also appear after cortical application of penicillin, whereas an 
injection of penicillin in the thalamus does not have this effect. This indicates that the 
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epileptiformic discharges are the result of abnormal responses of the cortex and not of 
the thalamus (Gloor et al., 1979; Gloor and Fariello, 1988). The crucial factor 
responsible for SWDs here is a presumed diffuse increase in the excitability of the 
cortex: cortical neurons respond to the afferent thalamo-cortical volleys by producing 
SWDs instead of passively transferring sleep spindles. In all, this theory assumes that 
the mechanism responsible for the genesis of SWDs is closely linked to the 
thalamocortical mechanism that generates sleep spindles. 
 
1.6 Recent achievements in animal models of absence epilepsy 
 
It is well accepted that sleep spindles and SWDs have a common thalamic pacemaker in 
the reticular thalamic nucleus (RTN) (Kostopoulos, 2000). Due to specific membrane 
properties and reciprocal interactions with thalamo-cortical relay (TCR) cells, neurons 
in the RTN are capable of producing intrinsic rhythmic bursts, which manifest 
themselves in field potentials such as sleep spindles. Surgical isolation of the RTN 
abolished rhythmic bursting in TCR cells, but bursting was preserved in RTN neurons 
(Steriade et al., 1985). Steriade and coworkers (for review see Steriade, 2003) 
demonstrated that TCR nuclei could only exhibit spontaneous spindle oscillations 
(7–14 Hz) when they receive projections from the RTN. These and similar studies were 
mainly done in cats in vivo and in the ferret in vitro (Von Krosigk et al., 1993). Basic 
cellular properties of thalamic cells were described and modeled, such as the different 
firing modalities (tonic and bursting), the crucial role of Ca2+ currents, and the 
longlasting hyperpolarization and subsequent calcium spike, that control the basic 
rhythmicity of thalamo-cortical oscillations (Destexhe and Sejnowski, 2002). 
In the last decade, genetic rodent models became the model of choice (Danober et al., 
1998; van Luijtelaar et al., 2002; Crunelli and Leresche, 2002; Coenen and van 
Luijtelaar, 2003; Depaulis and van Luijtelaar, 2006). Outcomes of studies in Genetic 
Absence Epilepsy Rats from Strasbourg (GAERS; Liu et al., 1991, 1992; Marescaux et 
al., 1984, 1992; Avanzini et al., 2000; Aker et al., 2002) and WAG/Rij rats (Inoue et al., 
1993), supported the idea that SWDs are triggered in the thalamus or, more specifically, 
in its lateral parts implying that cortical SWDs originate from the thalamus. 
Pharmacological studies showed that local injections of the GABAA agonist muscimol 
and a GABA transaminase inhibitor in the ventrobasal complex of the thalamus, 
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increases SWDs in GAERS, similar to systemic injections of GABAmimetics in 
GAERS and in WAG/Rij rats (Vergnes et al., 1984; Danober et al., 1998; Coenen and 
van Luijtelaar, 2003; Bouwman et al., 2004). Interestingly, local injections of muscimol 
in the RTN decreased SWDs (Liu et al., 1991), most likely by preventing local 
oscillatory activity (Danober et al., 1998). The results of these pharmacological studies 
point towards a role of thalamic GABAergic neurons in the control of SWDs and the 
differential role of two regions of the thalamus in their occurrence. Other evidence was 
based on lesion studies: SWDs in GAERS were suppressed after large electrolytic 
lesions of the lateral thalamus (Vergnes and Marescaux, 1992) and also after more 
restricted chemical lesions of the RTN (Avanzini et al., 1992, 1993). The same 
observations were made in WAG/Rij rats: SWDs were completely abolished after 
ibotenic lesions of large parts of the thalamus including the RTN (Meeren, 2002). 
However, rostral and caudal poles of the RTN seemed to antagonize each other in the 
sustaining of SWDs: Lesions in the rostral part of the RTN decreased the number of 
SWDs, but if lesions were restricted to the caudal and middle parts of the RTN, the 
incidence was unchanged or even increased (Meeren, 2002;van Luijtelaar and Welting, 
2001). Most likely, there exists an antagonistic relationship between the rostral and 
caudal RTN; the caudal region of the RTN may inhibit the activity of a hypothetical 
pacemaker of SWDs located in the rostral part. This pacemaker may be disinhibited 
after lesions of the caudal RTN, which would explain the increase in SWDs. 
Nevertheless, the findings of all these studies corroborate the cortico-reticular theory 
that the pacemaker is located in the lateral thalamus. Although it is currently believed 
that SWDs are initiated in the RTN, the synaptic organization of the rostral pole of the 
RTN of the non-epileptic ACI rat (Agouti Copenhagen Irish, commonly used as a 
control strain since these rats showed no or at least very few SWDs in a comparative 
strain study; Inoue et al., 1990) appears to be similar to that of the epileptic WAG/Rij 
rat, as studied with electron microscopy (van de Bovenkamp-Janssen et al., 2004a), 
while GAERS also failed to show any essential structural alterations in RTN neurons 
compared to non-epileptic rats, no neuronal loss occurred in the RTN of epileptic 
animals (Sabers et al.,1996). It needs to be remarked that some physiological and 
anatomical features in rodents‘ brains are crucially different from the feline brain and 
earlier theories were exclusively based on neurophysiological studies in cats. 
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This difference might provide unique particularities to the rodent models of epilepsy, or 
at least account for some of its differences. First, SWDs in cats occur with frequencies 
from 3 to 4.5 Hz, about the same as in humans, but rats have 7–11 Hz as the intraspike 
frequency in a train of SWDs (Drinkenburg et al., 1993; Midzianovskaia et al., 2001; 
Bosnyakova et al., 2006). Second, in cats GABAergic inhibitory interneurons are 
present throughout the thalamus, including its relay nuclei, which receive an additional 
inhibitory control from RTN cells (Jones, 1985). In rats, inhibitory interneurons are 
absent in almost all thalamic relay nuclei (Jones, 1985), except the lateral geniculate 
nucleus (LGN, Ohara et al., 1983); moreover, the LGN itself gets more powerful 
monosynaptic inhibitory afferents from the RTN then any other part of the rats‘ 
thalamus (Ohara et al., 1980, 1983). Therefore, intrinsic inhibition is absent in the 
largest part of the thalamus in rats and the vast majority of thalamic nuclei receive only 
external inhibitory inputs from the RTN. This may significantly influence the oscillatory 
activity of thalamic neurons and the properties of thalamo-cortical networks. 
Finally, the relative contributions of the cortex and thalamus and their exact 
mechanisms are still a matter of debate, and much of the controversies concerning the 
exact mechanisms can be ascribed to the usage of different experimental models 
(Blumenfeld, 2005). A putative disadvantage of the penicillin model is that the role of 
the cortex may be overemphasized because this model considers pharmacologically 
induced SWDs in cats, in which the seizures have slightly different mechanisms 
compared to spontaneous occurring SWDs in genetic rat models (Meeren, 2002). The 
study of mechanisms of the idiopathic types of epilepsy such as childhood absence 
epilepsy, however, may benefit from all the animal models that are nowadays available, 
including the genetic ones. 
 
1.7 The role of the cortex in generalized absence epilepsy revisited 
 
In their scheme for the generation of SWDs, the authors of the cortical theory did not 
assume a single focus or a focal area (Bancaud, 1969, 1972; Niedermeyer, 1996) nor did 
the authors of the cortico-reticular theory, who assumed a diffuse and global role of the 
cortex in the transformation of sleep spindles (Gloor, 1969; Gloor et al.,1990). 
Regarding the mechanisms of SWDs, both theories considered the cortex in general and 
did not address the specific local neurophysiological properties that could make one 
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cortical region more favourable for epileptogenesis than another, as is done in cases of 
focal epilepsies. Some studies in GAERS and WAG/Rij rats suggested a global role of 
the cortex in absence epilepsy after cortical deactivation was demonstrated by the 
spreading depression technique (unilateral diffusion of KCl resulted in immediate 
abolishment of SWDs not only in the injected cortex but also in the ipsilateral thalamus; 
Vergnes and Marescaux, 1992; Meeren, 2002). The same effect was found in cats with 
penicillin-induced SWDs during cortical spreading depression (Avoli and Gloor, 1981; 
Gloor et al., 1990). This observation was used as an argument for the corticoreticular 
theory that the cortex is a key element for generation of SWDs. The idea that an intact 
cortex interconnected in a thalamo-cortical network is a prerequisite for the occurrence 
of SWDs is also supported by the fact that surgical removal of the cortex abolishes 
SWDs, cortical slices do not show spontaneous, widely synchronized bursting activity, 
and that only in a thalamocortical slice preparation some stimulus-elicited oscillatory 
activity can be found if reciprocal thalamo-cortical connectivity was present (Avoli and 
Gloor, 1982; Tancredi et al., 2000). The cortico-reticular theory assumes that the cortex 
is more easily excitable in epileptic subjects than in nonepileptic ones. Consequently, 
the cortex produces abnormal paroxysmal responses to normal thalamic excitation. 
In such a way, thalamic sleep spindles, reaching the cortex through afferent volleys, 
could be transferred into SWDs (Kostopoulos, 2000). The penicillin model also showed 
that cortical blockade of GABAA receptors facilitates the presence of SWDs. 
Tolmacheva and colleagues (2004) investigated the excitability of the sensorimotor 
cortex for various types of afterdischarges and seizure types in WAG/Rij rats. No 
differences between WAG/Rij and ACI (non-epileptic control) rats were found in the 
seizure thresholds and afterdischarges irrespective of age, only the threshold for limbic 
seizures was reduced in WAG/Rij rats compared to ACI rats. Therefore, it does not 
seem likely that the cortex of WAG/Rij rats is in general more hyperexcitable than the 
cortex of nonepileptic control rats, at least in terms of thresholds of various types of 
epileptoform afterdischarges. Cortical excitability was also investigated in vitro. Some 
basic electrophysiological properties of cortical tissue in GAERS, WAG/Rij rats and in 
non-epileptic rats were not principally different. This mainly concerns passive cortical 
properties such as the complex waveform of the evoked local field potentials, the 
percentage of pyramidal neuron populations (intrinsically bursting and regular spiking 
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cells), and intrinsic membrane properties. (Luhmann et al., 1995; Avanzini et al., 1996; 
D‘Antuono et al., 2006).  
 
 
Figure 1.1. Schematic impression of the 5 theories on the origin of generalized absence epilepsy. On the 
left are the thalamic theories: the centrencephalic theory of Penfield and Jasper (1954) and the thalamic 
clock theory of Buzsáki (1988). On the right are the cortical theories: the cortical theory of Bancaud, 
Lüders and collegues and Niedermeyer (1972) and the cortical focus theory of Meeren et al (2002). In the 
middle is the corticoreticular theory of Gloor (1968) (modified from Lüders et al.,1984).  
 
 
 
1.8 A focal cortical theory of absence epilepsy in WAG/Rij rats 
 
The role of the cortex in triggering SWDs became more obvious after a comprehensive 
study of network mechanisms responsible for the immediate onset, widespread 
generalization and high synchrony of SWDs (Meeren et al., 2002). Simultaneous, 
recorded field potentials from multiple cortical and thalamic sites were studied. The 
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cortico-cortical, intrathalamic, and cortico-thalamic interrelationships between these 
field potentials were quantified using non-linear association analysis (Pijn et al., 1989). 
This method included direct measurements of the strength of association (the degree of 
correlation) and the time delay between signals recorded at different cortical and 
thalamic sites. These parameters together characterized functional coupling between 
populations of interacting neuronal populations. Fig. 1 illustrates a generalized SWD in 
the WAG/Rij rat and the results of the non-linear analyses, that is, the existence of a 
cortical focus originating from one of the 16 electrodes in the SmI (somatosensory 
cortex) (it is shown in graphs at the bottom, the starting point of arrows reflects the 
beginning of activity at the SmI in all eleven time frames). SWDs recorded at other 
cortical sites consistently lagged behind this focal site, with time delays that increased 
with electrode distance, resulting in a mean propagation velocity of about 1.5 m/s. 
Intrathalamic relationships were more complex and could not account for the observed 
cortical propagation pattern. Functionally interconnected cortical and thalamic sites 
appeared to influence each other, while the direction of this bidirectional coupling could 
vary throughout one seizure. However, during the first five hundred milliseconds the 
cortical focus was consistently found to lead its thalamic counterpart. Thereafter, the 
cortex and thalamus were found to alternately lead and lag in an unpredictable way. 
These results are incompatible with the common assumption that the thalamus acts as 
the primary driving source for the discharges. Instead, they indicate that a cortical focus 
plays a leading role in the origin of generalized SWDs characteristic of absence seizures 
in the rat. The large-scale synchronization characterizing bilateral synchronized SWDs 
appears to be mediated by the fast propagation of seizure activity from this focal site 
through cortico-cortical networks. Once the oscillation has been set into motion, 
however, the cortex and thalamus form a unified oscillatory network in which both 
structures drive each other. The role of the thalamus probably lies in providing a 
resonant circuitry to amplify and sustain the discharges (Meeren et al., 2002). It has 
been mentioned that the intrathalamic nuclei play a major role in synchronization and 
maintenance of neuronal oscillations (Seidenbecher and Pape, 2001). In light of these 
findings, it is proposed that the generation of bilaterally synchronous SWDs is only 
possible in an anatomically and functionally intact cortico-thalamic network that is in a 
suitable state. This most beneficial state is characterized by a light to moderate 
hyperpolarization of the intrinsically bursting cortical pyramidal cells and of the TCR 
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and the RTN cells, which makes them highly prone to produce high-frequency bursts of 
action potentials, as is the case during transitions from waking to sleeping, during 
drowsiness and light non-REM sleep, the most favorable vigilance states for the 
occurrence of SWDs in WAG/Rij rats (Drinkenburg et al., 1991; Coenen et al., 1991; 
Coenen, 1995). The initial event was the generation of an epileptic spike at the site of 
the cortical focus. Fig. 2 illustrates the pooled results of 8 WAG/Rij rats. In each of the 
8 rats investigated, the focal zone was found to occupy a small (2-5 mm) zone in the 
projective area of the snout and vibrissae, as was established with functional mapping 
using evoked potentials. SWDs were initiated in a distinct (perioral) area of the 
somatosensory cortex, SmI (Meeren et al., 2002). Also, Steriade (2006) concluded that 
in a feline seizure model with SWDs, the latter are generated in the neocortex and 
thalamic involvement was instigated by cortical evoked excitation of mainly RTN 
neurons. 
 
                 
Fig. 1.2. A generalized SWD recorded from the lateral convexity of the neocortex of a WAG/Rij rat. 
Results of the non-linear association analysis are presented underneath; calculations are done on EEG 
epochs of 500 ms. The thickness of the arrows represents the strength of the association, while the 
arrowheads point in the direction of the lagging site. The results of the analysis consistently suggest a 
cortical focus located in the projection area of the upper lip. SWDs recorded at other cortical sites lag 
behind the focal site with time delays that increase with electrode distance (adapted from Meeren et al., 
2002). 
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Fig. 1.3.  Pooled data from eight rats, in all animals leading sites of SWDs, filled symbols, located in the 
somatosensory cortex. Open symbols represent lagging sites. The numbers represent the coordinates of 
the cortical surface in mm with zero point at the Bregma. Leading sites of SWDs occupy an area with the 
anterior-posterior coordinates from 2 (anterior to the bregma) to 3 (posterior to the bregma) mm, 
extending laterally from 6 to 8mm (adapted from Meeren et al., 2002) 
 
1.9 Experimental support of the focal cortical theory: local Deactivation 
 
The role of the SmI in the incidence of SWDs was examined using unilateral 
microinjections (1 ml) of 2% lidocaine into the vibrissal area of SmI (Sitnikova and van 
Luijtelaar, 2004). As is known, lidocaine temporarily blocks sodium channels and 
reversibly prevents neuronal activity (Malpeli and Schiller, 1979; Tehovnik and 
Sommer, 1997). It was hypothesized that blocking the neural activity in the SmI would 
unilaterally eliminate the cortical trigger of SWDs, which might result in a temporary 
decrease in their number. This hypothesis was tested in WAG/Rij rats. Animals were 
equipped with four epidural recording electrodes: bilaterally over the frontal cortex, 
unilaterally in the occipital area, and in the SmI adjacent to the injected site. As a 
control, an equal amount of saline was injected in the same area. A decrease in the 
number of SWDs emerged immediately after injection of 2% lidocaine as compared to 
saline. The difference between lidocaine and saline treated animals gradually 
diminished within two hours after injection. These results demonstrate that 
pharmacological deactivation of the driving cortical source caused a temporary 
reduction in the frequency of SWDs, which was observed at all recording sites 
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suggesting that deactivation of a certain cortical area is capable of decreasing 
generalized spike-wave activity throughout the entire cortex. Taken together, our results 
imply a crucial role of the vibrissae projecting area of the neocortex in the process of 
initiating SWDs. A bilateral blockade is much more effective than an unilateral one, at 
least as implied by the results of a preliminary pharmacological study: bilateral local 
injections in the peri-oral region of the SmI of the sodium channel blocker phenytoin in 
WAG/Rij rats and GAERS showed an almost complete abolishment of SWDs, while 
systemic administration of the drug increased SWDs. An earlier study was performed in 
GAERS: the anti-absence drug ethosuximide was bilaterally injected at multiple cortical 
and thalamic loci. The incidence of SWDs was strongly diminished if ethosuximide was 
injected in the SmI, and not or much less when injected in other cortical areas or in 
thalamic sites (e.g. the RTN or ventral basal thalamic complex). Therefore, treatment 
within thalamic target nuclei is insufficient for ethosuximide to have the full anti-
absence effect; instead, the action of this agent may reside exclusively, or least 
primarily, in the cortex (Manning et al., 2003, 2004). 
The outcome of these studies demonstrated that the WAG/Rij rats are not unique in the 
existence and location of the focal cortical origin of SWDs. In a combined EEG, in situ 
hybridization and immunohistochemical study in WAG/Rij rats, it was found that some 
types of sodium channels (Nav1.1 and Nav1.6) were up regulated and over expressed 
selectively at ML +6mm in the transverse plane at bregma (Klein et al., 2004). This 
region of the cortex approximately matches the electrophysiologically determined 
region of seizure onset within the perioral area of the SmI (Meeren et al., 2002). The 
upregulation was age dependent (only in 5–6 months old rats, not in younger ones), and 
this corresponds with the age-dependent increase in SWDs. The findings of this very 
elegant study clearly show that the age-dependent increase in SWDs is closely related to 
the age-dependent upregulation of certain types of sodium channels in the superficial 
layers of the perioral area of the somatosensory cortex only. 
Neurophysiological studies showed functional differences in excitability in the 
somatosensory cortex between WAG/Rij rats and non-epileptic controls. An 
NMDAsensitive late EPSP that led to action potential discharges was found in 44% of 
regular bursting cells in the neocortical deep layers of WAG/Rij rats, and only in 8% of 
the cells in control rats in vitro (D‘Antuono et al., 2006). Inherent properties of 
hyperpolarisation-activated currents of pyramidal neurons (layers II–III) in the 
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somatosensory cortex of WAG/Rij rats differed in this area from those of two other rat 
strains (Wistar and ACI), and this modification of the physiological properties of 
neurons was accompanied by a reduced protein expression of subunits HCN1 (Strauss et 
al., 2004). It was proposed that the above-mentioned changes increase excitability 
especially in the perioral region of the SmI and thus facilitate the initiation of SWDs 
(Strauss et al., 2004). It is not clear however, whether these differences between strains 
are found exclusively in the perioral region of the somatosensory cortex or if other 
cortical regions differ between the epileptic and control rats. Therefore, it cannot be 
established that the perioral region of genetic epileptic rats is unique in the sense that 
only this region is hyperexcitable. High-level impairment of the inhibitory processes 
was found in the frontal cortex of WAG/Rij rats in vivo when compared to three other 
rat strains (ACI, APO-SUS and APO-UNSUS) in a paired pulse inhibition paradigm 
(sensory gating) while recording auditory evoked potentials (De Bruin et al., 2001), 
suggesting functional inhibitory disturbances in the neocortex of WAG/Rij rats. A 
functional change in the BOLD (blood-oxygen-leveldependent) signal during SWDs 
was found in fully conscious WAG/Rij rats. Significant increases in bold responses 
were found in widespread thalamic areas and the neocortex, including the SmI (Tenney 
et al., 2004). Other BOLD effects from functional MRI (fMRI) measurements (7 T) 
were measured in WAG/Rij rats under fentanyl/haloperidol anesthesia in combination 
with simultaneous recordings of field potentials (Nersesyan et al., 2004a, b). It was 
shown that spontaneous SWDs intensively involve the somatosensory area in addition 
to the thalamus and the electrical activity was accompanied by increased oxygen needs. 
 
1.10 Morpho-functional substrates of absence epilepsy in WAG/Rij rats 
 
1.10.1Cytoarchitectural abnormalities of the neocortex  
 
It is a common belief that typical absence epilepsy is a purely ‗‗functional‘‘ disease 
since no structural lesion of any kind has ever been identified (Berkovic et al., 1987; 
Niedermeyer, 1996). An increased number of dystrophic neurons were found in 
neocortex and the subcortical white matter of the frontal lobe in patients with absence 
epilepsy (Meencke, 1989). In animal models of absence epilepsy, the cellular structure 
of cortical tissue appears to have entirely escaped consideration. Within the framework 
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of the focal theory of absence seizures (Meeren et al., 2002), Karpova and co-workers 
examined the cytoarchitecture of the anterior part of the neocortex in WAG/Rij rats, 
paying attention to the frontal (motor) region and to the parietal cortex, including the 
perioral region of the SmI (Karpova et al., 2005). The cellular composition and 
geometry of dendrite trees were established with the Golgi-staining technique and this 
was followed by qualitative and quantitative morphometric analysis. Typical for both 
the SmI and motor cortex of WAG/Rij rats was a disorder in the distribution of 
pyramidal cells in the superficial cortical layers (I–III). Apical dendrites of superficial 
pyramidal cells were often split in two branches, declined and went in non-
perpendicular directions (Fig. 5). Quantitative morphometric measurements of dendrites 
such as the total length of dendrites, mean length of a dendritic segment and the size of 
the dendritic arbor, were increased when data from within and outside the epileptic area 
were compared, indicating that the pattern of dendritic arborization is abnormal in the 
epileptic zone in WAG/Rij rats. Disturbances in dendritic trees, a receptive part of 
pyramidal neurons, may cause impairment in communication between individual 
neurons. As mentioned, the differences were found in the superficial pyramidal cells, 
which, owing to long-range projections to remote cortical regions, may synchronize 
intrinsic cortical oscillations (Gray and McCormick, 1996). Therefore, the perioral area 
of SmI in WAG/Rij rats (the plausible trigger site of SWD) may express abnormal 
associations with other cortical areas that may facilitate synchronization and 
propagation of SWDs. 
Age-dependent changes in the cytoarchitecture of cortical neurons may facilitate 
absence epilepsy. In all rodent models of absence epilepsy, SWDs appear at the age of 
2–3 months and gradually increase with age (e.g. Coenen and van Luijtelaar, 1987; 
Willoughby and Mackenzie, 1992; Danober et al., 1998; Marescaux et al., 1992; Snead, 
1992; Schridde and van Luijtelaar, 2005), which could be due to aging processes. Aging 
has an effect on cytomorphometric parameters of neuronal and glial populations in the 
SmI of the limbs and in the frontal cortex in Wistar rats (Peinado et al., 1993, 1997). 
Using serial sections stained with cresyl-fast-violet and quantitative morphometric 
techniques, the cellular composure found in younger (4–6 months old) rats was 
compared to that in older (30–32 months old) subjects. Cortical volume and neuronal 
density did not change with age, while glial density was significantly increased in older 
rats (mean for all layers 17%). Also, cytometric parameters of neurons in layer II–IV 
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altered with age: the shape of neurons was changed (major/minor diameter ratio was 
decreased) and the area of the neuronal soma was diminished. The overwhelming 
majority of synapses in the SmI are excitatory. The ratio between excitatory and 
inhibitory synapses in young adults is 4.2:1, and in older animals (32 month old) it is 
4.9:1 (Poe et al., 2001). Therefore, there is a deficit in the intrinsic inhibitory circuitry of 
the aging neocortex that may contribute to a hyperexcitable state in the SmI and lead to 
absence seizures. Intracortical inhibition plays an important role in absence epilepsy, 
and genetic factors might influence this process of agerelated inhibitory impairment. In 
the following section more properties of the GABAergic system in the brain of 
WAG/Rij rats will be discussed. 
 
 
1.10.2 Impairment of the Gabaergic system: immonocytochemistry and 
neurophysiology 
 
It is already known for more than 10 years that synaptic network properties in the 
neocortex of WAG/Rij rats are impaired in comparison to non-epileptic Wistar controls. 
More precisely, the efficiency of GABAergic inhibition (as measured with intracellular 
recordings) is considerably reduced in the fronto-parietal cortical areas (Luhmann et al., 
1995). As is known, inhibitory GABAergic interneurons form 20% to 30% of the 
neocortical population; their axons are relatively short and rarely spread further than 
0.3mm (Peters and Jones, 1984; Markram et al., 2004). Inhibitory interneurons are 
subdivided into several classes: large, small and nested basket cells, chandelier cells, 
and double bouquet cells (for review see Markram et al., 2004). About 50% of all 
inhibitory interneurons are basket cells. They effectively control the firing activity of 
target cells (pyramidal and other interneurons): they synchronize the activity in neuronal 
networks. Basket cells typically express two calcium-binding proteins, parvalbumin 
(PV) and calbindin. PV is co-expressed with GABA in 90% of the GABAergic neurons 
(Miettinen et al., 1996; Celio, 1986), and PV-immunostaining is an appropriate way to 
mark basket cells (Kawaguchi and Kubota, 1997). This technique has been recently 
used in WAG/Rij rats to study the distribution of GABAergic neurons over various 
brain regions. It was suggested that an increase in cortical excitability in WAG/Rij rats 
and a low efficacy of the GABAergic inhibitory system could be the result of a smaller 
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amount of inhibitory neurons or from the impairment of metabolism of GABA in 
GABAergic neurons. The number of PV-immunopositive cells was quantified in 
various brain structures of WAG/Rij rats and compared with that in non-epileptic 
control ACI rats. It was found that some brain regions are much more strongly stained 
than others, like the molecular hippocampal layers and the thalamic nuclei, in agreement 
with data from, e.g. Houser et al. (1980). Both WAG/Rij and (non-epileptic control rats) 
ACI rats showed structures or even large cortical regions that hardly contained 
PVimmunoreactive cells. These cortical regions were not devoid of neurons but they 
simply could not be stained with the anti-PV serum. Apparently, these cells do not 
contain enough PV to become immunopositive. WAG/Rij rats showed a tendency to 
have more unstained regions than ACI rats but this difference was not statistically 
significant and no specific cortical area was consistently unstained in each WAG/Rij rat 
examined, demonstrating that there are individual differences in the affected regions. 
Quantification of PV-positive cells showed clear differences in the parietal (Par1) and in 
the forelimb area of the somatosensory cortex (FL), where ACI rats showed about two 
times as many PV-positive cells as WAG/Rij rats. Par1 and FL are parts of the 
somatosensory cortex, and Par1 contains the perioral projections. The lack of PV in 
these regions may destabilize intraneuronal Ca2+ homeostatic processes such as 
excitability, intracellular signaling and neurotransmitter release. Considering the co-
localization of PV with GAD and GABA, it is assumed that the cortex contains areas 
with a lesser amount or even a lack of GABAergic cells in both strains (WAG/Rij and 
ACI). Probably, in WAG/Rij rats PV-immunoreactive (GABAergic) neurons in the 
somatosensory cortex and olfactory tubercle contain less PV or PV could even be 
absent, which would cause local cortical alterations of inhibition. A neurophysiological 
study aimed to establish whether differences in excitability or inhibition could underlie 
the presence of a focal area. Local field potentials were investigated in coronal in vitro 
brain slices containing Par1 and FL of the somatosensory cortex of 6-month-old 
WAG/Rij rats and age-matched control Wistar rats (Pitra et al., 2005). Field potentials 
were evoked by paired electrical stimuli (20 ms interpulse interval) applied to layer V, 
and they were recorded in overlying sites within layer II/III. Generally, the magnitude 
of the response to the second stimulus of a pair is a result of interplay between short-
term dynamics of monosynaptic excitatory glutamatergic transmission and disynaptic 
inhibitory GABAergic transmission. 
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The amplitudes of responses to the first pulse of a pair were not different between 
WAG/Rij and control rats over the wide range of stimulation intensities, suggestive of a 
lack of difference in excitatory transmission in activated intracortical pathways of both 
strains. However, in WAG/Rij rats, a significantly smaller amount of paired-pulse 
depression of responses was observed in Par1 (Fig. 8b). This difference was not 
observed in the FL area. These results are consistent with a local and selective deficit in 
intracortical GABAergic transmission in WAG/Rij rats. In this sense it is extremely 
interesting that the local application of weak or strong GABAA antagonists in normal 
cats (penicillin and bicuculline) promotes the development of SWDs (Kostopoulos, 
2000; Steriade, 2003). The role of the GABAergic system has been more extensively 
investigated in GAERS than in WAG/Rij rats. The hypothesis that an abnormal cortical 
GABAergic activity may underlie absence seizures in GAERS was confirmed by 
differences between GAERS and controls in thresholds for GABA receptor antagonists 
and inhibitors of GABA synthesis (Vergnes et al., 2000). Moreover, it was found that 
GAERS are more prone to seizures elicited by cortical GABA deficiency (Brailowsky et 
al., 1999). However, the distribution and number of neurons immunoreactive for GABA 
and GAD (Spreafico et al., 1993) and expressing GAD65 and GAD67 mRNAs 
(Danober et al., 1998) were similar in the cerebral cortex of GAERS and in age-matched 
controls. Also, autoradiographic studies showed that ligands binding to GABAA 
receptor subtypes in the cortex were not altered in adult GAERS rat, or in other rats 
with spontaneous SWDs (Knight and Bowery, 1992; Spreafico et al., 1993). 
Immunohistochemical studies of the GABAA receptor subunits showed a moderate 
reduction in the intensity of immunostaining of the 2,3 subunits of the GABAA receptor, 
selectively in the cerebral cortex of adult GAERS rats. Interestingly, this reduction was 
not observed before the occurrence of absence seizures, suggesting that these 
differences are present only after repetition of seizures in adults (Spreafico et al., 1993). 
A high affinity to GABAB receptors was observed in cortical membranes prepared from 
adult GAERS, whereas the total number of these receptors was similar in epileptic and 
control strains (Mathivet et al., 1996). A combined autoradiography, in situ 
hybridization and immunocytochemical study of the GABAB receptor in the 
somatosensory cortex in GAERS showed results at variance, although a clear 
upregulation of GABAB receptor protein in the cortico-thalamic circuit in GAERS was 
found (Princivalle et al., 2003). A significant increase in the number of GABAB 
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receptors occurs in the cortex of lethargic mice, although the affinity of these receptors 
appears unchanged (Hosford et al., 1992; Caddick and Hosford, 1996). Both alterations 
of GABAB receptor composition could account for an increase in cortical excitation 
through disinhibition by presynaptic autoreceptors. However, it is by all means not clear 
whether these differences in GABA-mimetic properties are present throughout the 
frontal cortex or mainly in the perioral region of the somatosensory cortex, or whether 
they are the cause of the discharges or caused by the discharges. It is also not clear 
whether the WAG/Rij rats and GAERS share the same deficits in the GABAergic 
system since comparative studies are lacking. Anyway, a deficit in the GABAergic 
system may have two different consequences: on the one hand, the impairment in 
inhibition may cause hyperexcitation of intracortical microcircuits, as was suggested for 
the feline penicillin model (Gloor, 1979). Then, excitatory pyramidal cells may start 
producing paroxysmal bursts and cause absence seizures. On the other hand, inhibitory 
deficits may decrease synchrony within the cortex because a sufficient amount of 
inhibition is needed for the synchronization of pyramidal cell bursting activity. How and 
in which way a reduced number of GABAergic cells available for synchronizing the 
burst firing of pyramidal cells contribute to more SWDs when rats are getting older 
remains to be established.  
So, all this evidences  suggest that inhibitory mechanisms in WAG/Rij rats are impaired 
in such a way that seizures more easily appear in local cortical regions (probably due to 
hyperexcitation from a lack of inhibition) and rapidly spread over the brain due to 
disinhibition of pyramidal neurons with long-range projections. This might imply that 
intracortical and cortico-subcortical network associations are altered in WAG/Rij rats.  
 
1.10.3 Role of the Glutamatergic system in absence epilepsy 
 
Burst firing between reciprocally interconnected glutamatergic thalamic relay neurons 
in the ventral basal thalamus and neocortical pyramidal neurons is synchronized by 
GABAergic neurons in the nucleus reticularis thalamic (NRT) (Steriade et al., 1993; Oh 
et al.,1995; Cox et al., 1997; Kim et al., 1997; McCormick and Bal, 1997). 
Glutamatergic thalamic relay neurons in fact send projections to cortex, and layer 6 of 
cortex sends reciprocal glutamatergic projections back to the associated thalamic 
nucleus (Guillery, 1969; Montero and Singer, 1984). Both of these projections pass 
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through the NRT where emitting glutamatergic collaterals within the GABAergic 
reticular neurons (Steriade and Deschenes, 1984; Pinault et al., 1995a,b). Glutamatergic 
signaling occurs through both iGluRs and mGluRs within the NRT and each of the 
dorsal glutamatergic thalamic relay nuclei (Bal et al., 1995a; Godwin et al., 1996b; 
McCormick and von Krosigk, 1992; Salt and Eaton, 1996; Turner and Salt, 1998).  
The NRT-driven synchronization that drives the phasic oscillatory activity within this 
circuitry generates normal rhythms, such as sleep spindles, and pathological 
phenomena, such as bilaterally SWDs, that characterize generalized absence seizures 
(Snead, 1995; McCormick and Bal, 1997; Danober et al., 1998; Snead et al., 1999). 
Perturbations in the presynaptic release of glutamate and GABA within thalamocortical 
circuitry have been demonstrated in several animal models of absence seizures 
(Banerjee and Snead, 1995; Lin et al., 1995; Richards et al., 1995). Vigabatrin, a GABA 
transaminase inhibitor that increases the levels of endogenous GABA, is also known to 
enhance spike-wave discharges (Bouwman et al., 2003). Cortical synapses in both relay 
nuclei and the TRN show strong frequency-dependent facilitation (Alexander and 
Godwin, 2005; Alexander et al., 2006;Turner and Salt, 1998; Granseth et al., 2002). 
GABAergic thalamic reticular neurons project only to other thalamic reticular neurons 
and to their associated relay nuclei (Cucchiaro et al., 1991; Wang et al., 2001). 
GABAergic TRN cells activate chloride channel-associated GABAA receptors and G-
protein coupled GABAB receptors within the relay nuclei to which the TRN cells 
project (Sanchez-Vives and McCormick, 1997). According to the cortical focus theory, 
cortical hyperexcitation initiates 3Hz SWD activity patterns in part by driving TRN 
synchronization of activity within the thalamus, which contributes to the generalization 
of the seizure to cortex. Intracortical circuitry in layers 2/3 and 5 are also proposed to 
contribute to the initiation and generalization of seizures. 
The release of glutamate and GABA in thalamocortical circuitry is modulated by 
presynaptic metabotropic glutamate receptors (mGluRs) (East et al., 1995; Salt et al., 
1996; Cochilla and Alford, 1998; Schaffhauser et al., 1998), giving rise to the 
hypothesis that mGluRs also may play a role in the pathogenesis of absence seizures. 
The eight mGluR subtypes (mGluR1–mGluR8) have been classified into three groups 
on the basis of sequence homology, signal transduction mechanisms, and 
pharmacological profiles (Nakanishi, 1994; Pin and Duvoisin, 1995; Conn and Pin, 
1997). Activation of group III mGluRs inhibits the release of glutamate and GABA 
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from nerve terminals (East et al., 1995; Pin and Duvoisin, 1995; Neugebauer et al., 
1997; Schaffhauser et al., 1998). This subgroup of mGluRs is activated selectively by 
the glutamate analog L-amino-4-hosphonobutyrate (L-AP4). Among the group III 
mGluRs ultrastructural studies using mGluR4-specific antibodies consistently have 
shown a presynaptic localization for this receptor (Kinoshita et al., 1996; Shigemoto et 
al., 1997; Bradley et al., 1999). mGluR4 is highly expressed in the rodent (Thomsen and 
Hampson, 1999) and human thalamus (Makoff et al., 1996). The presence of mGluR4 
mRNA in the thalamic relay neurons (Ohishi et al., 1995) indicates that the receptor 
protein is expressed on the terminals of these neurons, which make synaptic contacts 
with neocortical pyramidal neurons and the GABAergic neurons in the NRT. 
 
1.11 Perioral area of SmI as a generator of intrinsic oscillations 
 
Meeren et al. (2002) suggested that there is a focal area within the somatosensory-
thalamo-cortical network—the projection area of the snout, vibrissae and upper lip—
from which SWDs initiate and drive the rest of the corticothalamic circuitry. The 
hypothesis that SWDs are initiated somewhere in the sensorimotor cortex was also 
proposed by Seidenbecher et al. (1998), based on work in GAERS. Before the fully 
developed paroxysm was evident on the gross EEG, precursor activity (‗‗embryonic‘‘ 
SW seizures) was typically recorded in cortical units and in the thalamus. The 
generation of SWDs was associated with spikeconcurrent, rhythmic burst-like activity 
in (mono-) synaptically connected regions of specific (somatosensory) thalamic areas, 
the SmI (layers IV/V), and the RTN. SWD-correlated activity in layers IV/V of the SmI 
started significantly earlier than correlated burst firing in reticular and in ventrobasal 
thalamic neurons (Seidenbecher et al., 1998). To understand why the projection area of 
the snout and vibrissae may be primarily involved in the initiation of SWDs, one should 
consider some peculiarities of this cortical region in rodents. The vibrissal system in rats 
has a very high behavioral relevance for survival and has evolved from the demands of 
a nocturnal environment in order to compensate for their poor vision. Interestingly, a 
genetic predisposition to absence epilepsy is more readily present in albino rats than in 
others since the incidence of SWDs is higher in albino than in hooded, brown and agouti 
rats (Inoue et al., 1990). Moreover, GAERS and old Wistar rats (van Luijtelaar et al., 
1995), both albinos, have abundant SWDs. Perhaps; the presence of the albino gene in 
33 
 
albino rats deteriorated the visual system while other sensory systems (such as the 
vibrissal system) might be more sensitive or have a larger receptive field. The SmI in 
rodents not only has great functional significance, it also has an exclusive ability to 
generate and sustain oscillations in the 7–12 Hz band. This has to be taken into account 
when rats and other rodent models are used as a model of absence epilepsy. Based on 
this theoretical issue and our own data (Meeren et al., 2002; Sitnikova and van 
Luijtelaar, 2004) as well as the above-mentioned reports of others, we introduced the 
concept that the perioral area of SmI in rodents with absence epilepsy has specific 
morpho-physiological properties to initiate and sustain a spontaneous 7–12 Hz rhythm. 
The SmI is able to activate a corticothalamo-cortical loop and facilitate epileptogenesis 
in rats with a genetic predisposition to absence seizures. The cortical area where the 
perioral projections in SmI can be found is a central part of the trigeminal system and is 
intimately involved in movements of the whiskers. Rats use these rhythmic whisker 
movements to obtain information about their extra-personal space. This behavioral state 
is called ‗‗whisking twitching‘‘ during which robust, coherent oscillations with a 
frequency of 7–12 Hz take place in the vibrissal areas of the brainstem, thalamus and 
SmI (Nicolelis et al., 1995; Nicolelis and Fanselow, 2002). SmI initiates whisking 
activity by producing these oscillations, or the somatosensory rhythm (Nicolelis et al., 
1995; Ahissar et al., 1997). This rhythm first appears at the cortical level as 
synchronous activity in the population of somatosensory neurons. It is less clear 
whether the somatosensory rhythm could easily be detected in the EEG or in local field 
potentials in rats as we never recorded it, even with monopolar microelectrodes in the 
SmI (Meeren et al., 2002; Sitnikova and van Luijtelaar, 2005). However, it can be 
observed with unit recordings. It has a cortical origin: the burst activity can be blocked 
by cortical lesions and by local injection of muscimol (GABAaagonist) into the vibrissal 
region of the SmI (Nicolelis and Fanselow, 2002). The various types of oscillations in 
rats, such as somatosensory rhythm, sleep spindles and SWDs have the same 
frequencies (7–12 Hz). Although functionally different, identical or parallel thalamo-
cortical circuits may generate these different 10 Hz rhythms: it cannot be excluded that 
the neuronal mechanisms underlying the generation of these different rhythms are the 
same (Nunez, 1995). It is well established that sleep spindles and SWDs in cats and 
WAG/Rij rats have the same cortical profile of sources and sinks (Kostopoulos et al., 
1982; Kandel and Buzsaki, 1997). The somatosensory rhythm begins during attentive 
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immobility and it reliably predicts the imminent onset of rhythmic whisker twitching. 
Others describe that the sensory mu rhythm is a state of being idle (Shaw and Liao, 
2005). SWDs do not regularly occur during attentive states but, rather, when the rats are 
mentally and physically passive (Coenen et al., 1991; van Luijtelaar et al., 1991). 
Therefore, it is not very likely that the somatosensory rhythm triggers SWDs; instead, 
when the rats are idle, oscillations might happen more easily, and the same circuitry that 
is involved in the generation of a mu rhythm might be used. Whether this is indeed the 
case, needs to be established. However, the somatosensory rhythm shares some 
properties with SWDs, such as the same frequency (Nicolelis et al., 1995; Drinkenburg 
et al., 1993); they are initiated in the same locus of the SmI, that is, in the projection 
areas of the vibrissae (Nicolelis et al., 1995; Meeren et al., 2002); they show a 
considerable topographical overlap and widely occupy the cortical and subcortical parts 
of the trigeminal system, including the ventroposterior complex of the specific thalamus 
(Inoue et al., 1993; Semba et al., 1980; Semba and Komisaruk, 1984; Nicolelis et al., 
1995); and unexpected sensory stimulation of vibrissae can terminate the ongoing 
‗‗somatosensory rhythm‘‘ (Ahissar et al., 1997) as well as SWDs (Coenen et al., 1991). 
These observations imply an intimate association between SWDs and the non-
paroxysmal somatosensory rhythm. It is proposed that not only in rats with the genetic 
predisposition to absence epilepsy, such as WAG/Rij rats (Coenen and van Luijtelaar, 
2003), GAERS Danober et al., 1998), but also in many old Wistar, WKY and Sprague–
Dawley (van Luijtelaar et al., 1995; Willoughby and Mackenzie, 1992) and Long Evans 
rats (Shaw and Liao, 2005; Polack and Charpier, 2006), normal somatosensory 
oscillations occurring during a less active brain state are transformed into SWDs, which 
could explain why so many albino rats slowly develop SWDs. During drowsiness, it is 
easier to trigger SWD oscillations and activate the corticothalamic network because 
cortical and thalamic neurons are already slightly hyperpolarized and firing in the 
favorable bursting mode. Wiest and Nicolelis (2003) hypothesized that in rodent strains 
with a genetic predisposition to absence epilepsy, 7–12 Hz rhythmic activity might 
undergo some transformation and give rise to SWDs, irrespective of whether it occurs 
during drowsiness, attentive wakefulness or during light non-REM sleep. The plasticity 
in neuro-molecular mechanisms (protein and enzyme synthesis, properties of ion 
channels and membranes, neurotransmission and neuromodulation, etc.) that might be a 
consequence of the genetic modifications in WAG/Rij rats (Coenen and van Luijtelaar, 
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2003), may alter cortical excitability and induce a decay in the efficacy of inhibition. 
This allows epileptic SWDs to emerge from physiological 7–12 Hz somatosensory 
oscillations. Neuronal mechanisms of oscillatory activity in SmI. Rhythmic activity in 
the neocortex occurs due to synchronous firing of the excitatory ‗‗intrinsically 
bursting‘‘ pyramidal cells and inhibitory interneurons (Fellous et al., 2001; Silva et al., 
1991; Steriade, 2001). Intrinsically bursting pyramidal neurons are located in the deep 
cortical layers and produce rhythmic recurrent spike bursts of 5–10 Hz (Connors and 
Gutnick, 1990; Flint and Connors, 1996). Network interactions with local inhibitory 
interneurons govern synchronization of bursting activity in a population of bursting 
neurons (Fellous et al., 2001): when a large number of neurons start firing in synchrony, 
a sharp 5–10 Hz rhythm can be recorded as a field potential. The firing pattern of 
cortical neurons significantly influences thalamic activity, since descending 
corticothalamic afferents are several times more dense than thalamo-cortical ascending 
ones (Rouiller and Welker, 2000). The pyramidal neurons of the deep cortical layers (V 
and VI) send dense descending projections to various subcortical structures; therefore, 
cortical oscillations could easily be transferred to the thalamus and other subcortical 
structures (Descheˆnes et al., 1998). These descending projections provide the RTN 
(Steriade, 2006) with many more excitatory inputs of the AMPA-GluR4 type than the 
TCR cells in the ventral basal complex, stimulating the GABA-ergic RTN to fire 
rhythmically and to inhibit the TCR cells. The differential descending excitatory inputs 
to the two parts of the thalamus were confirmed with quantitative data from both 
electron microscopy and neurophysiological recordings (Golshani et al., 2001). The 
cortical inputs produce excitation and rhythmic spike-bursts in RTN neurons. 
Interestingly, we found more AMPA-GluR4 receptors in the rostral RTN of WAG/Rij 
rats than in non-epileptic age-matched control rats and in younger WAG/Rij rats with 
no or very few SWDs (van de Bovenkamp-Janssen et al., 2006). This suggests that the 
RTN does react differently in genetic epileptic rats to corticofugal inputs and thus 
implies that the RTN produces more excitation and bursting than in non-epileptic 
animals. Construction of an oscillatory loop between SmI and subcortical structures. In 
order to produce high-voltage regular paroxysms as SWDs, cortical and thalamic 
neurons form so-called closed excitatory loops where cortical neurons are excited by 
thalamic neurons and cortical neurons excite the thalamus (rule of reciprocity). Cortical 
neurons also project to other thalamic nuclei that have no direct cortical terminals. 
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Therefore, corticothalamic connections comply with a more general rule, the rule of 
parity (Descheˆnes et al., 1998). With this type of connections, excitation could spread 
throughout and even beyond the thalamo-cortical system, so that paroxysmal activity 
could be found in different and selective parts of the brain (Steriade, 2003; Blumenfeld, 
2005). 
 
 
1.12 Perioral area of the SmI as a part of an oscillatory trigeminal system 
 
A low-amplitude tremor of the vibrissae or jaws can be observed when rats are standing 
still, immobile, or during a passive behavioral state (Semba et al., 1980; Semba and 
Komisaruk, 1984). This tremor-like whisker twitching occurred in synchrony with 
individual bursts of multiunit activity recorded in the ventrobasal complex of the 
thalamus and with ‗‗alpha‘‘ waves (SWDs) in the frontaloccipital EEG. In non-epileptic 
(and young) Long Evans rats, these rhythmic cortical EEG waves were considered as 
the equivalent of an idling (mu) rhythm (Shaw and Liao, 2005). The resting tremor 
became more severe in aged rats, and these animals often exhibited SWDs, which were 
also called high voltage spindles (HVS); they are however, asymmetric, there is a clear 
large amplitude spike and a slow wave, and the train of spikes and waves do not have 
the waxing and waning characteristic of spindles so therefore the name HVS is not 
appropriate (Shaw, 2004; Shaw and Liao, 2005). It was suggested that oscillations, 
which normally occur within the trigeminal vibrissae system, could be further 
transformed into absence-like seizures (SWDs). Considering that SWDs are initiated at 
the vibrissal area of the SmI, it is possible that SWDs as seen during waking 
(desynchronized EEG) might represent a transformed mu (somatosensory) rhythm 
(Sitnikova and van Luijtelaar, 2004). Even in the absence of explicit stimulation 
(perhaps being idle), rats emit patterns of rhythmic whisking movements with a 
frequency of 5–15 Hz (O‘Connor et al., 2002). The organization of these stereotyped 
movements involves at least three oscillatory loops. A dysfunction of this powerful 
oscillatory machinery as the vibrissal system in  rodents may easily lead to the 
appearance of pathological rhythms such as SWDs. Fig.1.4 shows that the 
thalamocortical circuit, which produces SWDs in rats, is to a certain extent part of the 
much larger multi-loop trigeminal system. In order to produce stable and high-
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amplitude oscillations, this loop needs top-bottom, reciprocal feed-forward and 
feedback connections. To spread more extensively in the brain, SWDs may use 
pathways of the trigeminal system and in this way may also invade more remote parts of 
the brain, including afferent and efferent brainstem projections of the whisker pathway. 
This may explain why absence seizures in rodents are often accompanied with certain 
latency by a tremor of the vibrissal system (van Luijtelaar and Coenen, 1986; Danober 
et al., 1998; Buzsaki et al., 1990). This peripheral activity ultimately interacts with 
superior parts of the oscillatory system and controls the frequency of ongoing 
oscillations. Local deafferentation of the mystacial pad with xylocaine significantly 
decreases the frequency of SWDs in Long Evans rats (Shaw and Liao, 2005). Therefore, 
rhythmical vibrissal tremor during absence seizures seems to provide an essential 
afferent control of oscillatory activity in the network where SWDs are generated. In 
summary, frequency-specific peripheral afferent input from trigeminal terminals is 
necessary for the thalamo-cortical circuit to synchronize its activity during SWDs. 
 
                                                            
Fig. 1.4. The architecture of the vibrissal (trigeminal) system in rodents that involves the hindbrain, 
cerebellar, and cortical loops (black arrows, see Kleinfeld et al., 1999, for more details). Thalamo-cortical 
circuit that sustains spike-wave discharges (SWDs) in WAG/Rij rats is indicated with thick gray arrows. 
This circuit is nested in a forebrain loop (Loop 1), therefore, the major pathways of SWDs largely use 
forebrain structures of the vibrissa sensorimotor system. The diagram illustrates the major pathways of 
the trigeminal oscillatory system. It overlaps partly with the cortico-thalamo-cortical loop in which the 
SWDs are generated. (From van Luijtelaar and Sitnikova, 2006) 
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1.13 Cytokines and absence seizures  
 
The actions of proinflammatory cytokines in the CNS are only at the beginning of being 
discovered; known is that their central actions include effects on the hypothalamo-
pituitary-adrenal (HPA) axis, but also pyrogenic and somnogenic effects have been 
described as well as a modification of the peripheral immune response (Schotanus, 
1995). Some cytokines have been recently shown to affect neurotransmitters, including 
monoamines, glutamate, GABA, and acetylcholine (ACh), to modulate the preservation 
of the synaptic strength at excitatory synapses, or affect the expression of various 
neuropeptides and neurotrophic factors in several brain regions (Rothwell and Hopkins, 
1995; Vezzani and Grenata, 2005). Changes in e.g. the neurotransmitter concentrations, 
some second messenger systems and Ca
2+
 currents induced by changes in the immune 
system may change the excitability of the central nervous system and alter the 
susceptibility of exogenous induced or genetically determined types of epilepsy (Kovacs 
et al., 2006).  
There is also some evidence for relations between the immune system and epilepsy. 
Clinical studies show that the immune system may be activated or disbalanced in 
childhood epilepsies such as Rasmussen encephalitis (Hauf et al., 2009) and in Lennox-
Gastaut syndrome (van Engelen et al., 1995). Increased concentrations of interleukin-6 
(IL-6) in cerebrospinal fluid and plasma in patients after tonic-clonic seizures were 
found and there was also some indication of an increased concentration of IL-1 receptor 
antagonist (IL-1RA) (Peltola et al., 2000). Experimental studies in rats show that the 
administration of interleukin-1 beta (IL-1β) prolongs the duration of kainic acid–
induced seizures, whereas its effects can be blocked by IL-1RA (Vezzani et al., 2000; 
2002). Experimentally triggered status epilepticus with either kainic acid injections in 
the hippocampus or electrical stimulation increased mRNA expression for hippocampal 
IL-1β, TNF-α and other cytokines (Vezzani et al., 1999). TNF-α treated rats showed 
more prolonged epileptiformic discharges than control rats and electrical stimulation of 
the amygdala enhanced the level of TNF-α in serum and brain tissue (Shandra et al., 
2002). In a model of status epilepticus in rats it was established that cytokines affect 
hyperexcitability (De Simoni et al., 2000). Kindling of the amygdala increased the 
expression of IL-1β and TNF-α mRNA in various brain areas including cortex, 
hippocampus and amygdala (Plata-Salaman et al., 2000). Recent work has implicated a 
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number of cytokines in seizure-related hippocampal pathology. IL-1 protects 
hippocampal neurons from subsequent kainic acid- induced death at the time of seizure 
initiation. IL-1 RA icv administration 10 min before and 10 min after systemic kainic 
acid injection protects neurons in all subfields of the hippocampus from damage in a 
dose-dependent manner (Jankowsky and Patterson, 2001). Both TNF-α and IL-1β 
enhanced pentylenetetrazole-induced seizures in mice (Yuhas et al., 1999). It can be 
concluded that cytokines including IL-1β and TNF-α are more readily expressed 
following seizures and that seizures can be aggravated when cytokines are added 
exogenously. Actually, cytokines and other growth factors can be said to affect all 
aspects of seizure pathology, i.e. seizure itself, neuronal death, neuronal birth, reactive 
gliosis and mossy fiber sprouting (Jankowsky and Patterson, 2001). 
Little is known about the role of these cytokines in other, less malign types of epilepsy 
such as childhood absence epilepsy. The availability of well accepted genetic absence 
models such as Genetic Absence Epileptic Rats from Strasbourg (GAERS) and 
WAG/Rij rats facilitates the research towards the interplay between seizure activity and 
cytokines. Rats of the WAG/Rij strain are endowed with a genetically determined type 
of epilepsy (Coenen et al., 1992; van Luijtelaar and Sitnikova, 2006). At an age of two 
to three months, quite few rats show spike-wave discharges (SWD) in their 
electroencephalogram (EEG), at six months of age, all rats show SWD concomitant 
with behavioural signs such as twitching of the vibrissae, accelerated breathing together 
with an otherwise immobile posture (van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 1987). Age matched ACI rats have much less SWD than WAG/Rij rats (de 
Bruin et al., 2000; Schridde and van Luijtelaar, 2004) and are therefore often used as 
controls.  
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-2- 
AIM OF THE STUDY 
 
Absence epilepsy is the most pure form of generalized epilepsy characterized in the 
EEG by widespread bilaterally synchronous spike-wave discharges (SWDs) caused by 
thalamo-cortical oscillations. Latest Cortical Focus theory suggests a consistent cortical 
―focus‖ within the peri-oral region of the somatosensory cortex. In order to raise the 
evidence of a focal cortical theory, structural and functional MRI data were collected in 
all the cerebral areas involved in spindles generation and propagation in a genetic model 
of absence epilepsy (Experiment 1). Four-months-old WAG/Rij rats were used as 
control (no SWDs) whereas nine-months-old rats (daily SWDs) were referred as 
experimental group. In order to exacerbate SWDs episodes, rats were treated with 
Vigabatrin. Moreover to provides chemical information about  different brain regions in 
Wag/Rij rats,  we performed MRS analysis for the measure of the levels of different 
metabolites which reflects specific cellular and biochemical processes (Experiment 2). 
It has become increasingly obvious during recent decades that genetic factors play a 
main role in the idiopathic generalized epilepsies, including absence epilepsy. In this 
view, gene-array analysis for cell signaling pathways involved in SWDs in different 
cerebral areas (experiment 3), and qPCR data (experiment 4) were performed and 
correlated with EEG data. 
The actions of proinflammatory cytokines in the CNS are only partially discovered. 
Some cytokines have been recently shown to affect neurotransmitters or are required to 
preserve the synaptic strength at excitatory synapses, or affect the expression of various 
neuropeptides and neurotrophic factors in several brain regions. Changes in the immune 
system may change the excitability of the CNS and alter the susceptibility of exogenous 
induced or genetically determined types of epilepsy. Here we investigate the role of two 
cytokines, IL-1β and TNF-α in WAG/Rij rats. Our hypothesis is that cerebral blood 
flow alterations and cytokines/chemokines release can modulate the occurrence of 
SWDs. Both controls and WAG/Rij rats were injected i.p. by TNF-α (2µg/kg) and IL-1β 
(2µg/kg) and EEG was recordered for 72h after the treatment (experiment 5). 
Furthermore, we analyzed the blood serum by ELISA method for TNF-α and IL-1β in 
control and epileptic animals (experiment 6). 
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Fig. 2.1 In the illustration is summarizing  the experiment design and number of animals used for 
experiments 1, 2, 3 and 4.  
 
      
Fig. 2.2 Schematic description of the experiment design and number of animals used for experiments 5. 
 
 
Fig. 2.3 Summary of the experimental design and number of animals used for experiments 6.  
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-3- 
EXPERIMENT 1: STRUCTURAL AND FUNCTIONAL MRI 
 
3.1 INTRODUCTION TO EXPERIMENT 1 
 
Usually most epileptic syndromes are associated with widespread structural and 
functional cerebral damage but  patients which suffer of absence epilepsy don‘t seems 
to show brain structural damage. Magnetic resonance imaging (MRI) is primarily a 
medical imaging technique most commonly used in radiology to visualize the structure 
and function of the body. It provides detailed images of the body in any plane. MRI 
provides much greater contrast between the different soft tissues of the body than 
computed tomography (CT) does, making it especially useful in neurological (brain), 
musculoskeletal, cardiovascular, and oncological (cancer) imaging. It uses no ionizing 
radiation, but uses a powerful magnetic field to align the nuclear magnetization of 
(usually) hydrogen atoms in water in the body. Radiofrequency fields are used to 
systematically alter the alignment of this magnetization, causing the hydrogen nuclei to 
produce a rotating magnetic field detectable by the scanner. This signal can be 
manipulated by additional magnetic fields to build up enough information to construct 
an image of the body. 
In order to raise the evidence of a focal cortical theory for absence epilepsy, we studied 
whether structural and functional damage or differences occurs in cerebral areas which 
are known more involved in absence epilepsy.  
 
3.1.1 T2 weighted and diffusion-weighted imaging (DWI) analysis  
 
We performed T2 weighted and diffusion-weighted imaging (DWI) in 7 cerebral 
regions; hippocampus, ventral and medial thalamus, supra- and sub-granular motor 
cortex and supra- and sub granular somatosensory cortex  in 9 months epileptic Wag/Rij 
compared to 4 months non-epileptic Wag/Rij. Diffusion-weighted imaging (DWI)  is 
provides image contrast based on differences in diffusion of water molecules within the 
brain. Diffusion within the brain is determined by a variety of factors including the type 
of molecule under investigation, the temperature and the microenvironmental 
architecture in which the diffusion takes place. For example, diffusion of molecules 
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within the cerebrospinal fluid (CSF) is less limited than diffusion of molecules within 
the intra- and intercellular space. By using the appropriate magnetic resonance 
sequences that are sensitive for diffusion, these differences in diffusion rates can be 
used to produce image contrast.  
The microstructural architecture as well as physiological factors influences the diffusion 
of water molecules within the brain. Within fiber tracts, the effective molecular 
diffusion is larger in the direction along the long axis of the fiber tract compared with 
the direction perpendicular to the fiber tract. 
 
3.1.2 Regional brain volumes (rCBV) and regional brain flow (rCBF) analysis 
 
In the same groups of animals and for the same 7 cerebral regions used for T2 and DWI 
analysis, we determined with functional magnetic resonance imaging, regional brain 
volumes (rCBV) and regional brain flow (rCBF)  in order to identify areas of major 
brain activation during spontaneous spike-and-wave discharges (SWDs). Functional 
MRI (fMRI) measures signal changes in the brain that are due to changing neural 
activity. Increased neural activity causes an increased demand for oxygen, and the 
vascular system actually overcompensates for this. The CBV method requires injection 
of a class of MRI contrast agents that are now in human clinical trials.  
 
3.2 MATERIALS AND METHODS 
 
Male Wag/Rij rats (300-350 g) were kept under controlled environmental parameters 
and veterinarian control. The animals were habituated to handling for at least 2 weeks 
prior to the procedures employed in the present study. The experiments received 
authorization from the Italian Ministry of Health and conformed with the principles of 
the NIH Guide for the Use and Care of Laboratory Animals and the European 
Community Council (86/609/EEC) directive. All efforts were made to minimize the 
number of animals used and avoid their suffering. Two groups af animals were used, 
epileptic 9 months old rats treated with a single intraperitoneal (i.p.) bolus of Vigabatrin  
(N=5) (500 mg/kg; Yamanouchi Pharma B.V., The Netherlands) dissolved in saline 
(0.9%) in a volume of 2 ml/kg, or physiological saline as control (N=5). Second group, 
non epileptic 4 months old rats, also treated with Vigabatrin (N=6) or saline (N=6) at 
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the same concentration used for the first group. MRI analysis was performed 12 h after 
ip treatment. All the animals were analyzed with structural (T2W and DWI) and 
functional (rCBV and rCBF) MRI in 7 cerebral regions; hippocampus, ventral and 
medial thalamus, supra- and sub-granular motor cortex and supra- and sub granular 
somatosensory cortex.   
Vigabatrin is irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-
T), the enzyme responsible for the catabolism of the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) in the brain (Hammond and Wilder, 1985). The doses of  
Vigabatrin administered were chosen based on previous reports that it produce 
anhancement of SWDs ( Bouwman et al., 2003). MRI experiments were performed 
using a Bruker Biospec Tomograph equipped with an Oxford, 33-cm-bore, horizontal 
magnet operating at 4.7 T. Animals were anesthetized with 1% halothane in 1 L of 
oxygen in air per minute (initial dose: 4% halothane); heart rate were monitored. The 
rats were placed into a 7.2-cm-i.d. bird cage transmitter coil. The signal was received 
through a 2-cm surface coil, actively decoupled from the transmitter coil, and placed 
directly on the animal's head.  
3.2.1  T2 Weighted Imaging (T2) and  Diffusion Weighted Imaging (DWI)  
After a sagittal scout spin-echo, twenty contiguous 1-mm-thick slices were imaged 
starting 1 mm posterior to the olfactory bulbs using a RARE sequence with repetition 
time (TR) of 5117 ms, echo time (TE) of 65 ms, field of view (FOV) =  3,5×3,5 cm
2
, 
number of averages (NEX) = 2, matrix size: 256×256,corresponding to an in-plane 
resolution of 137 x 137 µm
2
.  Five contiguous slices, selected region of interest, were 
then imaged using a diffusion-weighted spin-echo sequence, with TR of 2200 ms, TE of 
30 ms, two b-values (6 and 2000 s/mm2), and matrix size 128 × 64 for apparent 
diffusion coefficient (ADC) maps and  a multiecho spin-echo sequence with 10 echoes, 
TR of 2000 ms, and TE ranging from 20 to 200 ms for quantitative T2 mapping. Images 
were analyzed using the software ParaVision 3.0 (Bruker Medical, Ettlingen, Germany). 
For DWI, the apparent diffusion coefficient (ADC) maps of water in the brain were 
obtained by two-point linear fit of the logarithm of images intensity versus the b factors 
according to the expression:  
M(b)=M0*exp(−ADC*b). 
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Analogously,T2 maps were obtained by a least-squares nonlinear exponential fitting of 
the signal intensity to the expression:  
M(t)=M0*exp(−t/T2). 
 
ADC and T2 values were extracted from maps using the region-of-interest (ROI) 
method: 5 square ROIs of 2 × 2 pixels were defined in every selected brain region. 
 
3.2.2 rCBV and rCBF maps 
In this experiment an USPIO particle (Sinerem®, kindly supplied by Guerbet, Aulnay-
Sous-Bois, France) was used as a contrast agent. Sinerem® is constituted by an iron-
oxide core of about 6 nm diameter coated by dextran (coated particle dimensions of 
about 20 nm) and is characterized by a blood half-time longer than 2 h in rats. 
Sinerem® (6 mg iron/kg) was dissolved in saline and injected in the tail vein.The same 
five contiguous transversal slices, used for ADC and T2 maps,  were imaged using 
Gradient-Echo sequence before and two minutes after administration of Sinerem® with 
the following parameters: TR/ TE = 200/ 15 ms, flip angle = 30°, Field of view 4×4 cm2, 
matrix size 256×192 zero-filled at 256x256, slice thickness = 1,5 mm.  
After injection of a superparamagnetic contrast agent, the T2* relaxation rate in the 
brain decreases (compared to the preinjection baseline) proportionally to the local CBV 
times a certain function of the plasma concentration f(P) of the contrast agent, 
ΔR2*=k · f(P) · CBV=K’ · CBV, 
where the last equation holds when the agent reaches a plateau concentration in the 
blood, as in the case of Sinerem. For a gradient-echo sequence with echo time TE, the 
following equation correlates the natural logarithm (ln) of the ratio between signal 
intensity (SI) before and after contrast medium ln(SI(pre)/SI(post) to CBV:  
ln(SI(pre)/SI(post)) = (TE · (ΔR2*))=K · CBV. 
This equation shows that alterations in the local CBV can be probed by MRI 
acquisitions and, when keeping constant the contrast agent dose and acquisition 
parameters, also allows a comparison of CBV values between different animals. 
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Maps of rCBV were obtained using the algebra tool of ParaVision. Briefly, after 
absolute reconstruction of images, background noise below threshold value (fixed by 
the ParaVision software) was cut off, as routinely done. The ln of the ratio between the 
SI before and after contrast medium administration (R value) was then calculated pixel 
by pixel and displayed. Values of rCBV were measured using ROIs. 
For rCBF maps,first passage images were acquired during the arrival of the contrast 
agent in the brain. A snapshot flash sequence was used, with TR = 14,2  ms, TE = 10 ms, 
flip angle = 30°, matrix size 128×32 (zero filled at 128×128). A single slice 1,5mm 
thickness was acquired. The time interval among images was 0.1 sec: three images were 
acquired before and 97 images after the bolus administration of Sinerem. 
The dynamic data were then analyzed to calculate the peak enhancement and especially 
the relative TTP. The latter parameter is related to mean transit time and blood flow. 
TTP was evaluated on the signal intensity plot as the time point of maximal signal 
reduction. Relative TTP was obtained as a difference between TTP and time of arrival 
TA: rTTP = TTP−TA, where the time of arrival is the time for contrast material to arrive 
in the brain. 
Peak enhancements were calculated by the relation: (SImin-SIpre)/SIpre, where SImin 
is the signal intensity at the time of maximal signal drop and SIpre is the average signal 
intensity of three points before contrast administration. 
 
3.3 RESULTS 
 
3.3.1. T2 weighted and Diffusion-weighted maging (DWI) analysis 
 
T2 values, calculated from multiecho spin-echo acquisitions, clearly showed the overall 
pattern of changes in epileptic rats versus controls (p< 0.05), 12 h after vigabatrine 
treatment, highlighting the signal decrease in older animals (characterized by an 
augmented number of SWDs episodes) throughout the 3 regions involved in absence 
seizures (the primary circuity of SWDs): Supra somatosensory cortex (SS Supra; 4m: 
87.16±0.82, 9m: 83.43±0.90), Sub somatosensory cortex (SS Sub; 4m: 83.62±0.66, 9m: 
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81.28±0.72) and Lateral Thalamus (Lat Thal; 4m: 79,16±0.34, 9m: 76.40±0.40, 
Fig.3.1).  
 
      
Fig.3.1 Schematic representation of T2 values comparing epileptic nine months old versus control non 
epileptic four months old animals; *= difference for multiple areas in the same group of animals (p≤0.05), 
Arrows indicates differences between nine versus four months old rats.  
 
T2 values differ significantly also between SS Supra (87.16±0.82) and SS sub 
(83.62±0.66; p< 0.05) in 4 months old rats only.  
Vigabatrin and Age showed an interaction in the lateral thalamus (p<0.05). Considering 
treatment effects, Vigabatrin enhances T2 in the medial thalamus (Med Thal; p<0.05; 
see Tab.3.1). This interaction should be considered in view of the fact that the 
lateral thalamus contains GABAergic cells, which are well known to be vigabatrin 
targets (Meeren et al., 2002).  
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mean (ms) st. dev.
PBS 86,93 2,42
VIGABATTRIN 86,60 1,69
PBS 88,11 0,50
VIGABATTRIN 86,11 0,79
PBS 86,85 3,04
VIGABATTRIN 85,49 2,90
PBS 84,57 2,47
VIGABATTRIN 83,43 2,86
PBS 87,53 2,71
VIGABATTRIN 86,79 3,56
PBS 84,25 1,80
VIGABATTRIN 82,60 2,80
PBS 83,97 1,91
VIGABATTRIN 83,26 2,97
PBS 81,34 2,00
VIGABATTRIN 81,21 1,99
PBS 78,10 1,02
VIGABATTRIN 80,21 2,04
PBS 76,67 0,20
VIGABATTRIN 76,13 0,86
PBS 86,6 2,04
VIGABATTRIN 87,80 7,13
PBS 84,37 1,63
VIGABATTRIN 90,80 2,39
PBS 88,51 1,93
VIGABATTRIN 89,84 2,07
PBS 88,09 4,24
VIGABATTRIN 90,48 6,42
Regions Age Treatment
Medial Thalamus
Hippocampus
9 months
4 months
9 months
4 months
9 months
4 months
Motor cortex supra-
granular
Motor cortex sub-
granular
Somatosensory -cortex 
supra-granular
Somatosensory -cortex 
sub-granular
Lateral Thalamus
9 months
4 months
9 months
4 months
9 months
T2 (ms)
4 months
4 months
9 months
 
Tab.3.1 Summary of T2 values for all the experimental groups. Data are expressed as mean ± st. dev. 
 
 
 
Fig.3.2 Schematic representation of DWI results comparing epileptic 9 months old with control non 
epileptic 4 months old animals irrespective to treatment; *= significative difference for different areas in 
the same group of animals (p≤0.05), Arrows = significative differences 9 months Vs 4 months (p≤0.05) 
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Diffusion-weighted images, based on the sensitization of the MRI signal to the 
Brownian motion of water molecules, reveal maps of brain tissue water motion, 
resulting in hyperintense alterations. ADC maps of brain tissue water, calculated from 
DWI, showed consistent changes both in cortical and subcortical data. 
There is a highly significant difference (p<0.005) between cortical areas: sub SS 
(0.62±0.04) < supra SS (0.63±0.04) < sub MOT (0.66±0.05) < supra MOT (0.74±0.05). 
Thus, WAG/Rij rats have higher Supra than Sub values and less in SS cortex than 
in Mot cortex. 
 
mean st. dev.
PBS 0,77 0,02
VIGABATTRIN 0,73 0,06
PBS 0,76 0,05
VIGABATTRIN 0,67 0,02
PBS 0,70 0,03
VIGABATTRIN 0,70 0,06
PBS 0,65 0,02
VIGABATTRIN 0,62 0,03
PBS 0,65 0,03
VIGABATTRIN 0,65 0,05
PBS 0,65 0,05
VIGABATTRIN 0,60 0,02
PBS 0,63 0,03
VIGABATTRIN 0,64 0,02
PBS 0,62 0,04
VIGABATTRIN 0,58 0,02
PBS 0,69 0,02
VIGABATTRIN 0,67 0,03
PBS 0,46 0,04
VIGABATTRIN 0,67 0,03
PBS 0,77 0,05
VIGABATTRIN 0,81 0,04
PBS 0,75 0,06
VIGABATTRIN 0,78 0,03
PBS 0,80 0,05
VIGABATTRIN 0,75 0,04
PBS 0,71 0,04
VIGABATTRIN 0,69 0,05
Regions Age Treatment
Medial Thalamus
Hippocampus
9 months
4 months
9 months
4 months
9 months
4 months
Motor cortex supra-
granular
Motor cortex sub-
granular
Somatosensory -cortex 
supra-granular
Somatosensory -cortex 
sub-granular
Lateral Thalamus
9 months
4 months
9 months
4 months
9 months
DWI
4 months
4 months
9 months
 
Tab.3.2 Resume of DWI results for all the experimental groups. Data are expressed as mean ± st. dev 
 
Considering cortical DWI values, older rats show significant (p<0.05) lower values 
(0.65±0.01) than younger rats (0.68±0.01). DWI data showed lower values after 
Vigabatrin treatment (p<0.05). Considering drug and region interaction: Vigabatrin 
decreased DWI values in Hippo, not in other regions. Highly significative differences 
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(p<0.05) between subcortical areas have been observed in DWI values: Med Thal 
(0.77±0.05) > Hippo (0.74±0.06) > Lat Thal (0.67±0.05).  
 
 
3.3.2. Regional brain volumes (rCBV) and regional brain flow (rCBF) analysis  
 
rCBV data  obtained by images acquired with gradient-echo sequence before and after 
USPIO administration showed consistent changes both in cortical and subcortical data. 
In particular, subgranular layers (4973.08±1820.83) in the motor cortex were found to 
differ significantly if compared to supragranular layers (6036.12±1671.92; p< 0.05). 
However, this difference was not present in the somatosensory cortex. Differences were 
observed also in supragranular layers between motor (6036.12±1671.92) and 
somatosensory cortices (5023.34±1699.35; p<0.05); no differences have been noticed in 
the respective subgranular layers (Tab. 3.3). 
 
 
Fig.3.3 Schematic representation of rCBV results comparing epileptic 9 months old with control non 
epileptic 4 months old animals irrespective to treatment; *= significative difference for different areas in 
the same group of animals (p≤0.05). 
 
A highly significant (p<0.001) effect of Vigabatrin was reported. Treatment reduces 
rCBV and, in particular, the overall decrease after Viga is more evident in motor cortex 
(supragranular layer; PBS: 6840.76±1147.94, Viga: 5151.02±1756.64; p<0.05 and 
subgranular layer; PBS: 6277.62±1338.61, Viga: 3538.09±1004.30; p<0.001)  than 
other brain regions observed. There was no significant effect of age, nor a significant 
interaction between age and drug, neither between age, region, and drug. Interaction has 
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been observed between region and age,  and region and drug (Viga vs PBS) (p<0.05); 
post-hoc tests showed that the effect of vigabatrin was restricted to the motor cortex 
(p<0.05). The post-hoc tests did not show significant age differences for the four 
cortical regions. The data suggest that the habitual difference between supra- and 
subgranular layers had disappeared in the somatosensory cortex of WAG/Rij rats 
and that the effects of vigabatrin were restricted to the motor cortex. 
Referred to subcortical data, evident regional subcortical differences (p<0.001) between 
the 3 subcortical zones Hipp (6519.11±252.37) > Med thal (5513.89±260.41) > Lat thal 
(4281.14±269.01); There were no age effects, nor effects of Vigabatrin. 
 
mean st. dev.
PBS 7439,52 1234,56
VIGABATTRIN 5189,00 2443,32
PBS 6122,25 454,08
VIGABATTRIN 5113,04 984,71
PBS 5203,73 678,06
VIGABATTRIN 3209,26 1193,84
PBS 7566,29 3151,17
VIGABATTRIN 3866,94 757,52
PBS 5550,25 2618,65
VIGABATTRIN 4654,80 1908,82
PBS 5049,66 780,99
VIGABATTRIN 4733,26 959,94
PBS 4610,51 811,79
VIGABATTRIN 4137,45 1188,48
PBS 5237,98 768,21
VIGABATTRIN 4212,40 870,60
PBS 5025,00 1720,00
VIGABATTRIN 3504,00 1043,00
PBS 5121,00 924,00
VIGABATTRIN 3474,00 884,00
PBS 6310,00 1472,00
VIGABATTRIN 5454,00 867,00
PBS 4889,00 318,00
VIGABATTRIN 5403,00 1567,00
PBS 7203,00 1505,00
VIGABATTRIN 6466,00 951,00
PBS 6269,00 640,00
VIGABATTRIN 6138,00 1225,00
Regions Age Treatment
Medial Thalamus
Hippocampus
9 months
4 months
9 months
4 months
9 months
4 months
Motor cortex supra-
granular
Motor cortex sub-
granular
Somatosensory -cortex 
supra-granular
Somatosensory -cortex 
sub-granular
Lateral Thalamus
9 months
4 months
9 months
4 months
9 months
rCBV
4 months
4 months
9 months
 
Tab.3.3 Resume of rCBV results for all the experimental groups. Data are expressed as mean ± st. dev 
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Fig.3.4 Schematic representation of rCBF results comparing epileptic 9 months old with control non 
epileptic 4 months old animals irrespective to treatment; Arrows = significative differences 9 months Vs 
4 months (p≤0.05). 
 
Data of rCBF showed consistent changes both in cortical and subcortical regions.  
Significant region effect (p<0.01) emerged analyzing cortical data: post-hoc tests 
showed that the values from the Supragranular layer of the somatosensory cortex (SS 
supra) were lower (6.47±2.18) than of the other 3 cortical regions (SS sub; 6.89±2.06) 
(Mot supra; 7.16±1.69) (Mot sub; 7.24±1.48). Furthermore, a significant age effect was 
found (p<0.05); 9 months old rats had higher rCBF values (7.94±0.47) than 4 months 
old rats (6.10±0.45; see Fig. 3.4). There were no interactions, nor a vigabatrine effect.  
Furthermore, subcortical differences were found in rCBF (p<0.001). The highest values 
were found in the hippocampus (7.37±1.39), medial thalamus (6.68±1.97), and finally 
lateral thalamus (5.97±2.16). Significant (p<0.05) age effect was found; 9 months old 
rats had higher rCBF values (7.53±0.50) than 4 months old rats (5.98±0.47). 
Thus, rCBF data demonstrate cortical and subcortical regional differences and 
higher values for older animals in both cortical and subcortical regions.  
53 
 
mean st. dev.
PBS 5,62 1,67
VIGABATTRIN 7,07 2,13
PBS 8,26 0,31
VIGABATTRIN 8,17 0,17
PBS 6,01 1,15
VIGABATTRIN 6,78 1,77
PBS 8,67 0,49
VIGABATTRIN 7,64 0,64
PBS 4,50 2,54
VIGABATTRIN 6,69 2,37
PBS 7,73 0,29
VIGABATTRIN 7,39 1,06
PBS 5,24 2,16
VIGABATTRIN 6,96 2,77
PBS 7,92 0,56
VIGABATTRIN 7,75 1,04
PBS 4,53 2,70
VIGABATTRIN 5,85 2,80
PBS 7,26 0,41
VIGABATTRIN 6,54 0,66
PBS 4,85 2,20
VIGABATTRIN 7,11 2,30
PBS 7,38 0,45
VIGABATTRIN 7,75 0,62
PBS 6,11 1,22
VIGABATTRIN 7,44 1,71
PBS 8,10 0,30
VIGABATTRIN 8,18 0,42
Regions Age Treatment
Medial Thalamus
Hippocampus
9 months
4 months
9 months
4 months
9 months
4 months
Motor cortex supra-
granular
Motor cortex sub-
granular
Somatosensory -cortex 
supra-granular
Somatosensory -cortex 
sub-granular
Lateral Thalamus
9 months
4 months
9 months
4 months
9 months
rCBF
4 months
4 months
9 months
 
Tab.3.4 Summary of rCBF results for all the experimental groups. Data are expressed as mean ± st. dev 
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EXPERIMENT 2: MAGNETIC RESONANCE SPETTROSCOPY (MRS) 
 
4.1 INTRODUCTION TO EXPERIMENT 2 
 
MRS is used to measure the levels of different metabolites in body tissues. The main 
difference between standard MRI and MRS is that the frequency of the MR signal is 
used to encode different types of information. MRI uses high spatial resolution to 
generate anatomical images, whereas MRS provides chemical information about the 
tissues. Spatial location determines the frequency with MRI, whereas the tissue‘s 
chemical environment determines the frequency in MRS. Rather than images, MRS data 
are usually presented as line spectra, the area under each peak representing the relative 
concentration of nuclei detected for a given chemical species. There are many different 
brain metabolites that are commonly seen on the MR spectrum but in our experiment we 
considered 3 groups of metabolities; N-acetylaspartate (NAA) + N-acetyl-aspartyl-
glutamate (NAAG),  creatine (CR) + Phosphocreatine (PCr) and Glutamate (Glu) +  
Glutamine (Gln). Due to low signal/noise ratio we can consider only the metabolities 
which have SD<20%, only of this we can be sure that the value is correct.   
The common way to analyze clinical spectra is to look at metabolite ratios, 
glycerophosphoryl-choline (GPC) + phopshorylcholine (PCh) concentration is used as 
internal control, so all the concentrations of others metabolities are related to GPC+PCh 
concentration. 
Each metabolite reflects specific cellular and biochemical processes. NAA is a neuronal 
marker and decreases with any disease that adversely affects neuronal integrity. 
Creatine is an amino acid and provides a measure of energy stores. Glutamate is the 
predominant excitatory amino acid neurotransmitter in the brain. The observable MR 
metabolites provide powerful information, but unfortunately, many notable metabolites 
are not represented in brain MR spectra. DNA, RNA, most proteins, enzymes, and 
phospholipids are missing. Some key neurotransmitters, such as acetylcholine, 
dopamine, and serotonin, are absent. Either their concentrations are too low, or the 
molecules are invisible to MRS. 
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4.2 MATERIALS AND METHODS 
 
MRS experiments were carried out using a Biospec System (Bruker Biospin) equipped 
with a 4.7T horizontal Oxford Magnet , 33 cm bore size. A 72-mm internal diameter 
bird-cage coil  and a tranceiver surface soil for rat brain were used. 
Water signal was suppressed using VAPOR sequence  (120-150 Hz bandwidth) and 
spectra were acquired with a  point resolved spectroscopy (PRESS) sequence  for 
localized 1H-MRS spectroscopy with TR/TE=4000/11, number of scans from 256 to 
512 and 4 dummy scans. PRESS uses a combination of magnetic fields gradients and a 
frequency selective 180° pulses to select a three dimensional voxels of a well defined  
size (20 mm^3) in the regions of interest (ROIs) . 
 
A  reference spectra without water suppression were acquired for both  the  voxels. 
Peaks quantification relatively to Cho+PCho was performed by utilizing LCModel 
(Provencher, 2001).  
 
Two groups af animals were used, one group of epileptic 9 months old rats treated with 
a single intraperitoneal (i.p.) bolus of Vigabatrin  (N=5) (500 mg/kg; Yamanouchi 
Pharma B.V., The Netherlands) dissolved in saline (0.9%) in a volume of 2 ml/kg, or 
with physiological saline as control (N=5). Second group, non epileptic 4 months old 
rats, also treated with Vigabatrin (N=5) or saline (N=5) at the same concentration used 
for the first group. MRI analysis was performed 12 h after ip treatment and  for all the 
animals ROIs were positioned in lateral thalamus (LT) and somatosensory cortex (SS). 
Also in this experiment, rats were treated with Vigabatrin in order to exacerbate SWDs 
episodes. 
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4.3 RESULTS 
 
 (NAA+NAAG)/(Ch+Pch) (Cr+PCr)/(Ch+Pch) (Glu+Gln)/(Ch+Pch)
PBS 4m 5,18 ± 0,76 4,03 ± 0,34 7,46 ± 0,46
PBS 9m 5,12 ± 0,99 4,39 ± 0,26 6,15 ± 0,72
Vigabatrin 4m 6,04 ± 0,94 5,51 ± 1,43 8,90 ± 2,18
Vigabatrin 9m 6,75 ± 0,78 5,70 ± 0,68 9,03 ± 0,44
PBS 4m 8,34 ± 1,37 5,24 ± 0,46 10,78 ± 1,20
PBS 9m 7,44 ± 1.91 5,14 ± 0,71 8,89 ± 0,61
Vigabatrin 4m 9,35 ± 3,07 6,72 ± 0,49 12,35 ± 3,82
Vigabatrin 9m 9,94 ± 2,93 6,80 ± 1,27 13,47 ± 2,66
 Metabolites relative concentration (mean ± st. dev)
Groups Regions
Thalamus
Somatosensory 
cortex
 
Tab. 4.1 Schematic representation of MRS results. N-acetylaspartate(NAA), N-acetyl-aspartyl-glutamate 
(NAAG), choline (Ch), phopshorylcholine (PCh), creatine (CR), Phosphocreatine (PCr), Glutamate (Glu) 
and  Glutamine (Gln). GPC+PCh concentration is used as internal control, so all the concentrations of 
others metabolities are related to GPC+PCho concentration. Values are expressed as mean ± St.dev. 
 
MRS data indicate higher levels of Glutamate+Glutamine vs control after Vigabatrin 
treatment, both in the thalamus and in the somatosensory cortex in epileptic 9 months 
rats (p<0.005) (Fig. 4.1-4.2).  
Also the other groups of metabolities are enhanced by Vigabatrin injection in the 
thalamus of epileptic animals but this enhancing is only significative for 9 months old 
animals (p<0.05) (Fig. 4.1). Data point out the effect of  Vigabatrin on 
Creatine+Phosphocreatine concentration both for epileptic and non epileptic animals in 
the somatosensory cortex (p<0.05) (Fig. 4.2). 
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Fig.4.1 Representation of MRS results performed in the Thalamus of Wag/Rij rats comparing epileptic 9 
months animals treated with Vigabatrin or PBS vs control non epileptic treated animals. Relative 
concentrations of N-acetylaspartate(NAA) + N-acetyl-aspartyl-glutamate (NAAG), creatine (CR) + 
Phosphocreatine (PCr) and Glutamate (Glu) + Glutamine (Gln)  were related to choline (Ch) + 
phopshorylcholine (PCh) concentration used as internal standard.  *= (p≤0.05); **= (p≤0.005); 
 
Fig.4.2 Representation of MRS results performed in the Somatosensory cortex of Wag/Rij rats comparing 
epileptic 9 months animals treated with Vigabatrin or PBS vs control non epileptic treated animals. 
Relative concentrations of N-acetylaspartate(NAA) + N-acetyl-aspartyl-glutamate (NAAG), creatine 
(CR) + Phosphocreatine (PCr) and Glutamate (Glu) + Glutamine (Gln)  were related to choline (Ch) + 
phopshorylcholine (PCh) concentration used as internal standard.  *= (p≤0.05); **= (p≤0.005); 
58 
 
-5- 
EXPERIMENT 3: GENE ARRAY  
 
5.1 INTRODUCTION TO EXPERIMENT 3 
 
It has become increasingly obvious during recent decades that genetic factors play a 
main role in the idiopathic generalized epilepsies, including absence epilepsy. 
Evidence for a genetic predisposition in this type of epilepsy arose from twin studies, 
where it was found that both pairs of monozygotic twins suffered more frequently from 
this disorder than pairs of dizygotic twins (Lennox and Jolly, 1954).  
To determine whether specific cerebral regions are differently activated in a animal 
model of  absence seizures and  to identify characteristic genes involved in absence 
epilepsy  the present study analyzed  the expression of 113 genes rapresentative of 18 
signal transduction pathways. We used Microarray technology which utilizes RNA from 
tissue to simultaneously determine the expression levels of many genes.  
Microarrays are composed of a set of distinct, gene-specific, nucleic acid probes 
immobilized on a solid support. During a microarray experiment, RNA is enzymatically 
converted to labeled cDNA (complementary DNA) or cRNA, and then hybridized to the 
immobilized nucleic acid probe. The labeled target bound at each gene-specific spot is 
typically detected using chemiluminescent methods. The signal produced at each spot is 
representative of the amount of message in the original RNA sample. This microarray 
system provides a economical and productive methods  for monitoring a focused large 
panel of genes in a particular biological pathway or disease state.  In order to reveal 
changes in expression of biological important  subsets of genes, microarray data were 
subjected to hierarchical clustering and statistical parametric and non-parametric 
analysis. 
Validation of the direction and magnitude of changes in gene expression indicated by 
microarray analyses was performed by real-time quantitative polymerase chain reaction 
(qPCR) (see experiment 4). 
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5.2 MATERIALS AND METHODS 
 
Male WAG/Rij (~250–300 g) housed individually in standard polycarbonate cages in a 
temperature and humidity controlled environment on a 12:12 light–dark cycle (lights off 
at 0600 h). Animals had access to food and water ad libitum.  
For microarray experiments, two groups af animals were used, epileptic 9 months old 
rats treated with a single intraperitoneal (i.p.) bolus of Vigabatrin  (N=3) (500 mg/kg; 
Yamanouchi Pharma B.V., The Netherlands) dissolved in saline (0.9%) in a volume of 
2 ml/kg, or physiological saline as control (N=3). Second group, non epileptic 4 months 
old rats, also treated with Vigabatrin (N=3) or saline (N=3) at the same concentration 
used for the first group. Drugs were administered 12h prior to dissection of  cerebral 
tissue (at approximately  0900 pm) in a single dose via the intraperitoneal (i.p.) route. 
The doses of  Vigabatrin administered were chosen based on previous reports that it 
produce anhancement of SWDs ( Bouwman et al., 2003). 
 
Tissue preparation, in order to reduce variability of the results, the same investigator 
performed all of the dissections of rats brain for  microarray and qPCR  experiments. 
Approximately 12h following the drug or vehicle administration, animals were 
euthanized by decapitation and brains were rapidly removed and washed twice in ice-
cold phosphate buffered saline (PBS, pH=7.4) prior to dissection of the four regions of 
interested;  somatosensory cortex (peri-oral region) (Bregma 0.70 mm), visual cortex 
(bregma -4.80 mm), ventral and lateral thalamus (bregma -3.30 mm) (Fig. 5.1) 
Following dissection, brain tissue was placed into 300 μl of ice-cold Trizol reagent 
(Invitrogen) for isolation of total RNA. 
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Fig.5.1  The four rat brain regions dissected for  microarray experiments. 
 
RNA isolation, total RNA was extracted using Trizol reagent (Invitrogen) according to 
the manufacturer's directions. RNA from the tissues was isolated from each region per 
each rat individually and not pooled within treatment groups or regions (48 samples). 
RNA was then further purified by elution through an RNeasy minicolumn (Qiagen). 
Total RNA integrity and concentration were determined by an Eppendorf 
BioPhotometer, and RNA samples were stored at −80 °C until further analysis. 
 
Microarray procedures, 0.1-3 μg of total RNA from each tissue sample was used for 
complementary RNA (cRNA) synthesis, labeling and amplification according to 
TrueLabeling-AMP 2.0 reagent Kit (Superarray) instructions. Biotin-16-UTP was 
purchased from EnzoLife. cRNA was purified using ArrayGrade cRNA clean-up kit 
(Superarray). For each sample, 2-4 µg of labeled cRNA was then hybridized to the 
Oligo GEArray® Rat Signal Transduction PathwayFinder™ Microarray (which consist 
of 115 gene-specific 60-mer oligos probe sets, fixed in 8 columns and 16 rows) in 
according to Chemiluminescent detection Kit (Superarray) directions. Microarrays were 
then scanned and probe intensities were quantified using GEArray Expression Analysis 
Suite software (Fig. 5.2). 
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Fig.5.2  Schematic representation of the 3 steps required for microarray analysis. In the first step RNA 
from each tissue sample was used for cRNA synthesis, labeling and amplification, during this phase new 
RNA was producted containing Biotin-16-UTP. In the second step, labeled cRNA was hybridized to the 
Oligo GEArray® overnight and then detection of the chemioluminescent signal was made using 
photosensible paper. In the last step, Microarrays were scanned and probe intensities were quantified 
using GEArray Expression Analysis Suite software.  
 
 
Microarray data analysis, data from arrays were analyzed using GEArray Expression 
Analysis Suite (Superarray Bioscience Corporation). Quantitative expression values 
were corrected to the background, normalized with respect to the positive control genes 
included in the arrays, and reported as ratios to the mean values of normalization genes. 
In order to reveal changes in expression of different genes subsets, we prompted a 
comparative analysis of the profiles expression; in details, we compared Vigabatrin vs 
PBS treated animals, and epileptic 9 months old vs non epileptic 4 months old rats, 
calculating the ratio between the corrected and normalized value of expression of every 
gene. 
Moreover microarray data were subject to hierarchical clustering . Clustergram shows 
the correlation of the genes across the sperimental groups, genes that are more similar 
are joined. Dendogram showing clusters of genes based on average signal intensity  for 
each experimental group were obtained.  
62 
 
5.3 RESULTS 
 
Comparative analysis of the gene expression profiles of epileptic Wag/rij 9 months old 
vs non epileptic Wg/rij 4 months old rats (ignoring treatment and region) was made. In 
table 5.1 are reported the ratios of all the 113 genes.  
 
Position Gene Symbol Gene Description Fold change  
1 Ppia Peptidylprolyl isomerase A 1.00 
2 Atf2 Activating transcription factor 2 1.09 
3 Bax Bcl2-associated X protein 0.82 
4 Bcl2 B-cell leukemia/lymphoma 2 1.25 
5 Bcl2a1 B-cell leukemia/lymphoma 2 related protein A1 1.27 
6 Bcl2l1 Bcl2-like 1 0.92 
7 Birc1b Baculoviral IAP repeat-containing 1b 0.96 
8 Birc3 Baculoviral IAP repeat-containing 3 1.15 
9 RGD1562883 Similar to livin inhibitor of apoptosis isoform beta 
(predicted) 
0.97 
10 Bmp2 Bone morphogenetic protein 2 0.91 
11 Bmp4 Bone morphogenetic protein 4 1.02 
12 Brca1 Breast cancer 1 0.75 
13 Ccl2 Chemokine (C-C motif) ligand 2 1.14 
14 Ccl20 Chemokine (C-C motif) ligand 20 1.75 
15 Ccnd1 Cyclin D1 0.89 
16 Cd5 CD5 antigen 0.82 
17 Cdh1 Cadherin 1 1.10 
18 Cdk2 Cyclin dependent kinase 2 0.72 
19 Cdkn1a Cyclin-dependent kinase inhibitor 1A 0.99 
20 Cdkn1b Cyclin-dependent kinase inhibitor 1B 0.50 
21 Cdkn1c Cyclin-dependent kinase inhibitor 1C (P57) 0.92 
22 Cdkn2a Cyclin-dependent kinase inhibitor 2A 0.74 
23 Cdkn2b Cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 
1.14 
24 Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18, inhibits 
CDK4) 
1.50 
25 Cdkn2d Similar to cyclin-dependent kinase inhibitor 2D 0.89 
26 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.05 
27 Csf2 Colony stimulating factor 2 (granulocyte-
macrophage) 
0.92 
28 Csn2 Casein beta 0.77 
29 Ctsd Cathepsin D 0.97 
30 Cxcl1 Chemokine (C-X-C motif) ligand 1 1.20 
31 Cxcl9 Chemokine (C-X-C motif) ligand 9 2.58 
32 Cyp19a1 Cytochrome P450, family 19, subfamily a, 
polypeptide 1 
2.31 
33 Egfr Epidermal growth factor receptor 0.97 
34 Egr1 Early growth response 1 0.85 
35 Ei24 Etoposide induced 2.4 mRNA 1.06 
36 Fasn Fatty acid synthase 1.08 
37 Fgf4 Fibroblast growth factor 4 0.88 
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38 Fn1 Fibronectin 1 1.03 
39 Fos FBJ murine osteosarcoma viral oncogene homolog 0.68 
40 Foxa2 Forkhead box A2 3.10 
41 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 0.88 
42 LOC690987 Similar to glycogen synthase 1, muscle 0.66 
43 Gys2 Glycogen synthase 2 1.02 
44 RGD1564108 Similar to hedgehog-interacting protein (predicted) 1.59 
45 Hk2 Hexokinase 2 1.03 
46 Hoxa1 Homeo box A1 0.68 
47 Hoxb1 Homeo box B1 (predicted) 1.95 
48 Hsf1 Heat shock transcription factor 1 1.41 
49 Hspb1 Heat shock 27kDa protein 1 0.97 
50 Hspca Heat shock protein 1, alpha 1.00 
51 Hspcal3 Heat shock 90kDa protein 1, alpha-like 3 (predicted) 0.99 
52 Icam1 Intercellular adhesion molecule 1 1.55 
53 Igfbp3 Insulin-like growth factor binding protein 3 0.79 
54 Igfbp4 Insulin-like growth factor binding protein 4 1.13 
55 Ikbkb Inhibitor of kappaB kinase beta 1.46 
56 Il1a Interleukin 1 alpha 3.44 
57 Il2 Interleukin 2 1.10 
58 Il2ra Interleukin 2 receptor, alpha chain 0.81 
59 Il4 Interleukin 4 0.69 
60 Il4ra Interleukin 4 receptor, alpha 1.04 
61 Irf1 Interferon regulatory factor 1 1.02 
62 Jun Jun oncogene 1.08 
63 Junb Jun-B oncogene 1.00 
64 Klkb1 Kallikrein B, plasma 1 3.72 
65 Lef1 Lymphoid enhancer binding factor 1 0.76 
66 Lep Leptin 0.66 
67 LOC685360 Similar to Homeobox protein engrailed-1 (Mo-En-1) 1.62 
68 Lta Lymphotoxin A 1.25 
69 Mdm2 Transformed mouse 3T3 cell double minute 2 0.84 
70 Mmp10 Matrix metallopeptidase 10 0.68 
71 Mmp7 Matrix metallopeptidase 7 0.82 
72 Myc Myelocytomatosis viral oncogene homolog (avian) 1.41 
73 Nab2 Ngfi-A binding protein 2 0.72 
74 Nfkb1 Nuclear factor of kappa light chain gene enhancer in 
B-cells 1, p105 
0.71 
75 Nfkbia Nuclear factor of k light chain gene enhancer in B-
cells inhibitor, α 
1.12 
76 Ngfg Nerve growth factor, gamma 0.84 
77 Nos2 Nitric oxide synthase 2, inducible 0.56 
78 Odc1 Ornithine decarboxylase 1 0.91 
79 Pecam Platelet/endothelial cell adhesion molecule 1.08 
80 Pgr Progesterone receptor 0.74 
81 Pparg Peroxisome proliferator activated receptor gamma 1.70 
82 Prkca Protein kinase C, alpha 0.74 
83 Prkcb1 Protein kinase C, beta 1 1.03 
84 Prkce Protein kinase C, epsilon 0.63 
85 Ptch Patched homolog 1 (Drosophila) 0.55 
86 Ptch1 Patched homolog 1 (Drosophila) 1.12 
87 Pten Phosphatase and tensin homolog 0.60 
88 Ptgs2 Prostaglandin-endoperoxide synthase 2 0.87 
64 
 
89 Pzp Pregnancy-zone protein 1.24 
90 Rbp1 Retinol binding protein 1, cellular 1.32 
91 Rbp2 Retinol binding protein 2, cellular 0.91 
92 Sele Selectin, endothelial cell 0.81 
93 Selp Selectin, platelet 0.45 
94 Stra6 Stimulated by retinoic acid gene 6 homolog (mouse) 0.41 
95 Tank TRAF family member-associated Nf-kappa B 
activator 
0.68 
96 Tcf7 Transcription factor 7, T-cell specific (predicted) 0.90 
97 Tert Telomerase reverse transcriptase 1.07 
98 Tfrc Transferrin receptor 0.69 
99 Tmepai Transmembrane, prostate androgen induced RNA 
(predicted) 
1.02 
100 Tmprss9 Transmembrane serine protease 9 (predicted) 0.70 
101 Tnf Tumor necrosis factor (TNF superfamily, member 2) 0.26 
102 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 
10b (predicted) 
0.49 
103 Tnfrsf6 Tumor necrosis factor receptor superfamily, member 
6 
0.79 
104 Faslg Fas ligand (TNF superfamily, member 6) 1.08 
105 Tp53 Tumor protein p53 1.00 
106 Trim25 Tripartite motif protein 25 (mapped) 0.60 
107 Vcam1 Vascular cell adhesion molecule 1 0.68 
108 Vegfa Vascular endothelial growth factor A 0.47 
109 Vegfc Vascular endothelial growth factor C 0.46 
110 Wisp1 WNT1 inducible signaling pathway protein 1 0.68 
111 Wisp2 WNT1 inducible signaling pathway protein 2 0.85 
112 Wnt1 Wingless-type MMTV integration site family, 
member 1 (mapped) 
0.87 
113 Wnt2 Wingless-related MMTV integration site 2 0.62 
114 Wsb1 WD repeat and SOCS box-containing 1 0.61 
 
Tab. 5.1 Comparative analysis of the gene expression profiles of epileptic Wag/rij 9 months old vs non 
epileptic Wg/rij 4 months old rats (ignoring treatment and region). Data are reported as ratio (Fold 
Change) between the corrected and normalized value of expression of every gene in the two groups. 
 
 
Genes were considered significantly over-expressed in one group when their expression 
values proved ≥ 1.25-fold higher than the expression of the same gene in the other 
group. On the other hand, genes were considered significantly under-expressed in one 
lineage when their expression values were ≤ 0.75-fold that of the expression of the same 
gene in the other group. In table 5.2 are reported all the over-expressed genes for every 
characteristic biological pathway. Since 5 out of 16 up-regulated genes belong to the  
NFkB pathway, it seems to be the biological pathway more implicated in the develop of 
the absence seizures in epileptic older animals. 
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Position Gene Symbol Gene Description Fold change 
5 Bcl2a1 B-cell leukemia/lymphoma 2 related protein A1 1.27
14 Ccl20 Chemokine (C-C motif) l igand 20 1.75
52 Icam1 Intercellular adhesion molecule 1 1.55
55 Ikbkb Inhibitor of kappaB kinase beta 1.46
56 Il1a Interleukin 1 alpha 3.44
NFkB Pathway
Position Gene Symbol Gene Description Fold change 
47 Hoxb1 Homeo box B1 (predicted) 1.95
67 LOC685360 Similar to Homeobox protein engrailed-1 (Mo-En-1) 1.62
90 Rbp1 Retinol binding protein 1, cellular 1.32
Retinoic Acid Pathway
Position Gene Symbol Gene Description Fold change 
48 Hsf1 Heat shock transcription factor 1 1.41
72 Myc Myelocytomatosis viral oncogene homolog (avian) 1.41
Stress Pathway
Position Gene Symbol Gene Description Fold change 
32 Cyp19a1 Cytochrome P450, family 19, subfamily a, polypeptide 1 2.31
CREB Pathway
Position Gene Symbol Gene Description Fold change 
64 Klkb1 Kallikrein B, plasma 1 3.72
Androgen Pathway
Position Gene Symbol Gene Description Fold change 
40 Foxa2 Forkhead box A2 3.10
Hedgehog Pathway
Position Gene Symbol Gene Description Fold change 
31 Cxcl9 Chemokine (C-X-C motif) l igand 9 2.58
Jak-Stat Pathway
Position Gene Symbol Gene Description Fold change 
81 Pparg Peroxisome proliferator activated receptor gamma 1.70
Wnt Pathway
Position Gene Symbol Gene Description Fold change 
24 Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 1.50
TGF β Pathway
 
Tab 5.2 List of all the over-expressed genes (Fold change ≥ 1.25) for the specifical biological pathway 
comparing epileptic Wag/rij 9 months old vs non epileptic Wg/rij 4 months old rats.  
66 
 
In table 5.3 are reported all the under-expressed genes for every characteristic biological 
pathway. Also in this case, the most implicated pathway seems to be the NFkB pathway 
(5 of the 31 total down-regulated genes). 
 
Position Gene Symbol Gene Description Fold change 
74 Nfkb1 Nuclear factor of kappa light chain gene enhancer in B-cells 1, p105 0.71
77 Nos2 Nitric oxide synthase 2, inducible 0.56
95 Tank TRAF family member-associated Nf-kappa B activator 0.68
101 Tnf Tumor necrosis factor (TNF superfamily, member 2) 0.26
107 Vcam1 Vascular cell adhesion molecule 1 0.68
NFkB Pathway
Position Gene Symbol Gene Description Fold change 
82 Prkca Protein kinase C, alpha 0.74
84 Prkce Protein kinase C, epsilon 0.63
98 Tfrc Transferrin receptor 0.69
Calcium and Protein Kinase C  Pathway
Position Gene Symbol Gene Description Fold change 
12 Brca1 Breast cancer 1 0.75
80 Pgr Progesterone receptor 0.74
106 Trim25 Tripartite motif protein 25 (mapped) 0.60
Estrogen Pathway
Position Gene Symbol Gene Description Fold change 
108 Vegfa Vascular endothelial growth factor A 0.47
109 Vegfc Vascular endothelial growth factor C 0.46
110 Wisp1 WNT1 inducible signaling pathway protein 1 0.68
Wnt Pathway
Position Gene Symbol Gene Description Fold change 
85 Ptch Patched homolog 1 (Drosophila) 0.55
113 Wnt2 Wingless-related MMTV integration site 2 0.62
114 Wsb1 WD repeat and SOCS box-containing 1 0.61
Hedgehog Pathway
Position Gene Symbol Gene Description Fold change 
20 Cdkn1b Cyclin-dependent kinase inhibitor 1B 0.50
22 Cdkn2a Cyclin-dependent kinase inhibitor 2A 0.74
TGF β Pathway
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Position Gene Symbol Gene Description Fold change 
46 Hoxa1 Homeo box A1 0.68
94 Stra6 Stimulated by retinoic acid gene 6 homolog (mouse) 0.41
Retinoic Acid Pathway
Position Gene Symbol Gene Description Fold change 
59 Il4 Interleukin 4 0.69
70 Mmp10 Matrix metallopeptidase 10 0.68
Jak-Stat Pathway
Position Gene Symbol Gene Description Fold change 
18 Cdk2 Cyclin dependent kinase 2 0.72
100 Tmprss9 Transmembrane serine protease 9 (predicted) 0.70
Androgen Pathway
Position Gene Symbol Gene Description Fold change 
87 Pten Phosphatase and tensin homolog 0.60
P13 Kinase/AKT Pathway
Position Gene Symbol Gene Description Fold change 
66 Lep Leptin 0.66
Insuline Pathway
Position Gene Symbol Gene Description Fold change 
102 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b (predicted) 0.49
P53 Pathway
Position Gene Symbol Gene Description Fold change 
93 Selp Selectin, platelet 0.45
LDL Pathway
Position Gene Symbol Gene Description Fold change 
73 Nab2 Ngfi-A binding protein 2 0.72
Mitogenic Pathway
Position Gene Symbol Gene Description Fold change 
39 Fos FBJ murine osteosarcoma viral oncogene homolog 0.68
Stress Pathway
 
Tab 5.3 List of the under-expressed genes (Fold change ≤ 0.75) for the specifical biological pathway 
comparing epileptic Wag/rij 9 months old vs non epileptic Wg/rij 4 months old rats. 
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Comparative analysis of the gene expression profiles in Wag/Rij rats after Vigabatrin 
treatment vs PBS treatment (ignoring age and region) was made. In table 5.4 are 
reported the ratios of all the 113 genes.  
 
Position Gene 
Symbol 
Gene Description Fold change  
1 Ppia Peptidylprolyl isomerase A 0.98 
2 Atf2 Activating transcription factor 2 1.52 
3 Bax Bcl2-associated X protein 1.62 
4 Bcl2 B-cell leukemia/lymphoma 2 3.09 
5 Bcl2a1 B-cell leukemia/lymphoma 2 related protein A1 2.20 
6 Bcl2l1 Bcl2-like 1 2.78 
7 Birc1b Baculoviral IAP repeat-containing 1b 2.39 
8 Birc3 Baculoviral IAP repeat-containing 3 2.54 
9 RGD156288
3 
Similar to livin inhibitor of apoptosis isoform beta (predicted) 1.62 
10 Bmp2 Bone morphogenetic protein 2 2.22 
11 Bmp4 Bone morphogenetic protein 4 1.86 
12 Brca1 Breast cancer 1 2.78 
13 Ccl2 Chemokine (C-C motif) ligand 2 2.63 
14 Ccl20 Chemokine (C-C motif) ligand 20 2.28 
15 Ccnd1 Cyclin D1 1.37 
16 Cd5 CD5 antigen 2.66 
17 Cdh1 Cadherin 1 2.00 
18 Cdk2 Cyclin dependent kinase 2 2.34 
19 Cdkn1a Cyclin-dependent kinase inhibitor 1A 1.80 
20 Cdkn1b Cyclin-dependent kinase inhibitor 1B 1.60 
21 Cdkn1c Cyclin-dependent kinase inhibitor 1C (P57) 2.30 
22 Cdkn2a Cyclin-dependent kinase inhibitor 2A 2.54 
23 Cdkn2b Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2.73 
24 Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 2.65 
25 Cdkn2d Similar to cyclin-dependent kinase inhibitor 2D 2.87 
26 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 2.30 
27 Csf2 Colony stimulating factor 2 (granulocyte-macrophage) 1.89 
28 Csn2 Casein beta 2.67 
29 Ctsd Cathepsin D 1.11 
30 Cxcl1 Chemokine (C-X-C motif) ligand 1 1.82 
31 Cxcl9 Chemokine (C-X-C motif) ligand 9 3.11 
32 Cyp19a1 Cytochrome P450, family 19, subfamily a, polypeptide 1 2.41 
33 Egfr Epidermal growth factor receptor 1.41 
34 Egr1 Early growth response 1 1.16 
35 Ei24 Etoposide induced 2.4 mRNA 1.21 
36 Fasn Fatty acid synthase 1.29 
37 Fgf4 Fibroblast growth factor 4 2.17 
38 Fn1 Fibronectin 1 1.60 
39 Fos FBJ murine osteosarcoma viral oncogene homolog 1.30 
40 Foxa2 Forkhead box A2 2.41 
41 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 2.64 
42 LOC690987 Similar to glycogen synthase 1, muscle 1.96 
43 Gys2 Glycogen synthase 2 2.65 
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44 RGD156410
8 
Similar to hedgehog-interacting protein (predicted) 3.67 
45 Hk2 Hexokinase 2 4.15 
46 Hoxa1 Homeo box A1 3.46 
47 Hoxb1 Homeo box B1 (predicted) 5.26 
48 Hsf1 Heat shock transcription factor 1 2.23 
49 Hspb1 Heat shock 27kDa protein 1 1.24 
50 Hspca Heat shock protein 1, alpha 1.00 
51 Hspcal3 Heat shock 90kDa protein 1, alpha-like 3 (predicted) 1.20 
52 Icam1 Intercellular adhesion molecule 1 3.01 
53 Igfbp3 Insulin-like growth factor binding protein 3 2.10 
54 Igfbp4 Insulin-like growth factor binding protein 4 3.40 
55 Ikbkb Inhibitor of kappaB kinase beta 4.20 
56 Il1a Interleukin 1 alpha 4.92 
57 Il2 Interleukin 2 2.07 
58 Il2ra Interleukin 2 receptor, alpha chain 1.56 
59 Il4 Interleukin 4 2.79 
60 Il4ra Interleukin 4 receptor, alpha 1.93 
61 Irf1 Interferon regulatory factor 1 2.25 
62 Jun Jun oncogene 1.19 
63 Junb Jun-B oncogene 4.24 
64 Klkb1 Kallikrein B, plasma 1 7.55 
65 Lef1 Lymphoid enhancer binding factor 1 2.26 
66 Lep Leptin 3.50 
67 LOC685360 Similar to Homeobox protein engrailed-1 (Mo-En-1) 4.75 
68 Lta Lymphotoxin A 4.81 
69 Mdm2 Transformed mouse 3T3 cell double minute 2 2.94 
70 Mmp10 Matrix metallopeptidase 10 4.54 
71 Mmp7 Matrix metallopeptidase 7 2.96 
72 Myc Myelocytomatosis viral oncogene homolog (avian) 3.55 
73 Nab2 Ngfi-A binding protein 2 2.82 
74 Nfkb1 Nuclear factor of kappa light chain gene enhancer in B-cells 1, 
p105 
2.54 
75 Nfkbia Nuclear factor of k light chain gene enhancer in B-cells 
inhibitor, α 
1.80 
76 Ngfg Nerve growth factor, gamma 2.58 
77 Nos2 Nitric oxide synthase 2, inducible 3.15 
78 Odc1 Ornithine decarboxylase 1 1.95 
79 Pecam Platelet/endothelial cell adhesion molecule 4.97 
80 Pgr Progesterone receptor 1.98 
81 Pparg Peroxisome proliferator activated receptor gamma 2.26 
82 Prkca Protein kinase C, alpha 2.24 
83 Prkcb1 Protein kinase C, beta 1 1.17 
84 Prkce Protein kinase C, epsilon 1.82 
85 Ptch Patched homolog 1 (Drosophila) 2.34 
86 Ptch1 Patched homolog 1 (Drosophila) 3.54 
87 Pten Phosphatase and tensin homolog 1.92 
88 Ptgs2 Prostaglandin-endoperoxide synthase 2 1.70 
89 Pzp Pregnancy-zone protein 2.74 
90 Rbp1 Retinol binding protein 1, cellular 1.66 
91 Rbp2 Retinol binding protein 2, cellular 1.34 
92 Sele Selectin, endothelial cell 1.95 
93 Selp Selectin, platelet 2.06 
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94 Stra6 Stimulated by retinoic acid gene 6 homolog (mouse) 2.97 
95 Tank TRAF family member-associated Nf-kappa B activator 2.36 
96 Tcf7 Transcription factor 7, T-cell specific (predicted) 3.38 
97 Tert Telomerase reverse transcriptase 2.45 
98 Tfrc Transferrin receptor 1.71 
99 Tmepai Transmembrane, prostate androgen induced RNA (predicted) 1.11 
100 Tmprss9 Transmembrane serine protease 9 (predicted) 2.64 
101 Tnf Tumor necrosis factor (TNF superfamily, member 2) 1.71 
102 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b 
(predicted) 
1.86 
103 Tnfrsf6 Tumor necrosis factor receptor superfamily, member 6 2.75 
104 Faslg Fas ligand (TNF superfamily, member 6) 2.51 
105 Tp53 Tumor protein p53 1.30 
106 Trim25 Tripartite motif protein 25 (mapped) 2.20 
107 Vcam1 Vascular cell adhesion molecule 1 1.34 
108 Vegfa Vascular endothelial growth factor A 1.78 
109 Vegfc Vascular endothelial growth factor C 1.81 
110 Wisp1 WNT1 inducible signaling pathway protein 1 1.73 
111 Wisp2 WNT1 inducible signaling pathway protein 2 1.76 
112 Wnt1 Wingless-type MMTV integration site family, member 1 
(mapped) 
1.63 
113 Wnt2 Wingless-related MMTV integration site 2 1.35 
114 Wsb1 WD repeat and SOCS box-containing 1 1.32 
 
Tab. 5.4 Comparative analysis of the gene expression profiles of all Vigabatrin treated Wag/Rij  vs PBS 
treated (ignoring age and region). Data are reported as ratio (Fold Change) between the corrected ana 
normalized value of expression of every gene in the two groups. 
 
Genes were considered significantly over-expressed in one group when their expression 
values proved ≥ 1.50-fold higher than the expression of the same gene in the other 
group. No under-expressed genes (Fold change ≤ 0.50)  were finded out comparing 
Vigabatrin treaed animals with control PBS treated animals. In table 5.5 are reported all 
the over-expressed genes for every characteristic biological pathway. 
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Position Gene Symbol Gene Description Fold change 
5 Bcl2a1 B-cell leukemia/lymphoma 2 related protein A1 2,20
7 Birc1b Baculoviral IAP repeat-containing 1b 2,39
8 Birc3 Baculoviral IAP repeat-containing 3 2,54
14 Ccl20 Chemokine (C-C motif) l igand 20 2,28
30 Cxcl1 Chemokine (C-X-C motif) l igand 1 1,82
52 Icam1 Intercellular adhesion molecule 1 3,01
55 Ikbkb Inhibitor of kappaB kinase beta 4,20
56 Il1a Interleukin 1 alpha 4,92
57 Il2 Interleukin 2 2,07
68 Lta(TNFβ) Lymphotoxin A 4,81
74 Nfkb1 Nuclear factor of kappa light chain gene enhancer in B-cells 1, p105 2,54
75 Nfkbia Nuclear factor of k l ight chain gene enhancer in B-cells inhibitor, α 1,80
77 Nos2 Nitric oxide synthase 2, inducible 3,15
79 Pecam Platelet/endothelial cell  adhesion molecule 4,97
95 Tank TRAF family member-associated Nf-kappa B activator 2,36
97 Tert Telomerase reverse transcriptase 2,45
101 Tnfα Tumor necrosis factor (TNF superfamily, member 2) 1,71
NFkB Pathway
Position Gene Symbol Gene Description Fold change 
17 Cdh1 Cadherin 1 2,00
37 Fgf4 Fibroblast growth factor 4 2,17
65 Lef1 Lymphoid enhancer binding factor 1 2,26
81 Pparg Peroxisome proliferator activated receptor gamma 2,26
96 Tcf7 Transcription factor 7, T-cell specific (predicted) 3,38
108 Vegfa Vascular endothelial growth factor A 1,78
109 Vegfc Vascular endothelial growth factor C 1,81
110 Wisp1 WNT1 inducible signaling pathway protein 1 1,73
111 Wisp2 WNT1 inducible signaling pathway protein 2 1,76
Wnt Pathway
Position Gene Symbol Gene Description Fold change 
27 Csf2 Colony stimulating factor 2 (granulocyte-macrophage) 1,89
58 Il2ra Interleukin 2 receptor, alpha chain 1,56
72 Myc Myelocytomatosis viral oncogene homolog (avian) 3,55
78 Odc1 Ornithine decarboxylase 1 1,95
82 Prkca Protein kinase C, alpha 2,24
84 Prkce Protein kinase C, epsilon 1,82
98 Tfrc Transferrin receptor 1,71
Calcium and Protein Kinase C  Pathway
Position Gene Symbol Gene Description Fold change 
10 Bmp2 Bone morphogenetic protein 2 2,22
11 Bmp4 Bone morphogenetic protein 4 1,86
40 Foxa2 Forkhead box A2 2,41
67 LOC685360 Similar to Homeobox protein engrailed-1 (Mo-En-1) 4,75
85 Ptch Patched homolog 1 (Drosophila) 2,34
86 Ptch1 Patched homolog 1 (Drosophila) 3,54
112 Wnt1 Wingless-type MMTV integration site family, member 1 (mapped) 1,63
Hedgehog Pathway
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Position Gene Symbol Gene Description Fold change 
19 Cdkn1a Cyclin-dependent kinase inhibitor 1A 1,80
20 Cdkn1b Cyclin-dependent kinase inhibitor 1B 1,60
21 Cdkn1c Cyclin-dependent kinase inhibitor 1C (P57) 2,30
22 Cdkn2a Cyclin-dependent kinase inhibitor 2A 2,54
23 Cdkn2b Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2,73
24 Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 2,65
25 Cdkn2d Similar to cyclin-dependent kinase inhibitor 2D 2,87
TGF β Pathway
Position Gene Symbol Gene Description Fold change 
28 Csn2 Casein beta 2,67
31 Cxcl9 Chemokine (C-X-C motif) l igand 9 3,11
59 Il4 Interleukin 4 2,79
60 Il4ra Interleukin 4 receptor, alpha 1,93
61 Irf1 Interferon regulatory factor 1 2,25
70 Mmp10 Matrix metallopeptidase 10 4,54
89 Pzp Pregnancy-zone protein 2,74
Jak-Stat Pathway
Position Gene Symbol Gene Description Fold change 
3 Bax Bcl2-associated X protein 1,62
41 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 2,64
53 Igfbp3 Insulin-like growth factor binding protein 3 2,10
69 Mdm2 Transformed mouse 3T3 cell double minute 2 2,94
102 Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b (predicted) 1,86
103 Tnfrsf6 Tumor necrosis factor receptor superfamily, member 6 2,75
P53 Pathway
Position Gene Symbol Gene Description Fold change 
4 Bcl2 B-cell leukemia/lymphoma 2 3,09
12 Brca1 Breast cancer 1 2,78
54 Igfbp4 Insulin-like growth factor binding protein 4 3,40
80 Pgr Progesterone receptor 1,98
106 Trim25 Tripartite motif protein 25 (mapped) 2,20
Estrogen Pathway
Position Gene Symbol Gene Description Fold change 
46 Hoxa1 Homeo box A1 3,46
47 Hoxb1 Homeo box B1 (predicted) 5,26
90 Rbp1 Retinol binding protein 1, cellular 1,66
94 Stra6 Stimulated by retinoic acid gene 6 homolog (mouse) 2,97
Retinoic Acid Pathway
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Position Gene Symbol Gene Description Fold change 
18 Cdk2 Cyclin dependent kinase 2 2,34
64 Klkb1 Kallikrein B, plasma 1 7,55
76 Ngfg Nerve growth factor, gamma 2,58
100 Tmprss9 Transmembrane serine protease 9 (predicted) 2,64
Androgen Pathway
Position Gene Symbol Gene Description Fold change 
26 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 2,30
43 Gys2 Glycogen synthase 2 2,65
45 Hk2 Hexokinase 2 4,15
66 Lep Leptin 3,50
Insuline Pathway
Position Gene Symbol Gene Description Fold change 
38 Fn1 Fibronectin 1 1,60
71 Mmp7 Matrix metallopeptidase 7 2,96
87 Pten Phosphatase and tensin homolog 1,92
P13 Kinase/AKT Pathway
Position Gene Symbol Gene Description Fold change 
13 Ccl2 Chemokine (C-C motif) l igand 2 2,63
92 Sele Selectin, endothelial cell 1,95
93 Selp Selectin, platelet 2,06
LDL Pathway
Position Gene Symbol Gene Description Fold change 
2 Atf2 Activating transcription factor 2 1,52
48 Hsf1 Heat shock transcription factor 1 2,23
Stress Pathway
Position Gene Symbol Gene Description Fold change 
63 Junb Jun-B oncogene 4,24
88 Ptgs2 Prostaglandin-endoperoxide synthase 2 (Cox-2) 1,70
Phospholipase C Pathway
Position Gene Symbol Gene Description Fold change 
73 Nab2 Ngfi-A binding protein 2 2,82
Mitogenic Pathway
Position Gene Symbol Gene Description Fold change 
6 Bcl2l1 Bcl2-like 1 2,78
Jak/Src Pathway
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Position Gene Symbol Gene Description Fold change 
16 Cd5 CD5 antigen 2,66
NFAT Pathway
Position Gene Symbol Gene Description Fold change 
32 Cyp19a1 Cytochrome P450, family 19, subfamily a, polypeptide 1 2,41
CREB Pathway
 
Tab 5.5 List of all the over-expressed genes (Fold change ≥ 1.50) for the specifical biological pathway 
comparing Vigabatrin treaed Wag/rij 9 vs PBS treated Wg/Rij. 
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Fig. 5.3 Clustergram shows the correlation of the genes across the sperimental groups in order to reveal 
changes in expressions associated to age of animals, treatment or different brain regions. Groups that have 
similar profile of expression are joined and showed on the top side of the dendogram, symbols of genes 
are along the left side. 
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EXPERIMENT 4; REAL TIME QUANTITATIVE PCR ANALYSIS (RT-qPCR) 
6.1 INTRODUCTION TO EXPERIMENT 4 
 
In order to validate the direction and magnitude of changes in gene expression indicated 
by microarray analyses, was performed real-time qPCR  for analyze the expression  of 
transcripts encoding B-cell CLL/lymphoma 2 (Bcl2), early growth response 1 (Egr1), 
fatty acid synthase (Fasn), tumor necrosis factor alpha (Tnf α) and tumor necrosis factor 
receptor superfamily, member 10b (Tnfrsf10b) . 
 
6.2 MATERIAL AND METHODS 
 
Wag/Rij treatmented with Vigabatrin (n=4; two 9 months and two 4 months) or saline 
(n=4; two 9 months and two 4 months) and tissues preparation and total RNA isolation 
were prompted in accordance with microarray experimental protocol (see experiment 
3). Reverse transcription of the RNA was performed  in 20 µL reaction volumes from 
1.5 µg RNA using 200 ng of random primers, 4 µL 5x First strand buffer, 0.5 µL RNasi 
Hinibitor, 0.5mM of dNTP and 200U of MoMLV reverse-transcriptase (Superscript II). 
The cDNA synthesis was performed at 42˚C for 2 hour before inactivation at 70˚C for 
10 minutes.  
Primers pairs were designed with Primer3 software (Table 6.1).  Amplification, data 
acquisition, and data analysis were carried out in the Biorad iQ5. Dissociation curves of 
PCR products were run to verify amplification of the correct product. For 25-µL 
reaction , 3 ng of cDNA template was mixed with 400 nM of each primer and iQ 2X 
SYBR Green Supermix (Biorad, Hercules CA) . The reaction was allowed to proceed 
for 90 seconds at 95 ˚C for for denaturation, followed by 55 cycles of 95 ˚C for 10 
seconds and 62 ˚C for 30 seconds for annealing/extension. The comparative cycle 
threshold (Ct) method was used for relative quantification. Data were normalized to the 
levels of RNA encoding 18S as housekeeping gene. Relative differences were 
subsequently calculated using the 2
-∆∆Ct
 method (Livak and Schmittgen, 2001). The 
Threshold cycle (Ct) mean of any sample was compared with the Ct mean obtained for 
the control gene, so ∆Ct = Ct (sample) – Ct (control). Then was calculated ∆∆Ct per 
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groups ΔΔCT=ΔCT (target) –ΔCT (reference). (for example I want to see AGE 
EFFECT;  ∆∆Ct = ∆Ct 9months-∆Ct 4months!). Fold change = 2-∆∆Ct. 
 
Gene Forwad Primer 5’ to 3’ Reverse Primer 5’ to 3’ 
Egr1 
Bcl2 
Fasn 
Tnf α 
Tnfrsf10b 
18s 
AGC AGC GCT TTC AAT CCT C 
 
GAG CAG CGT CTT CAG AGA CA 
 
AGC TGT TCC TCC AGC TCC TT 
 
GAC CCT CAC ACT CAG ATC ATC TTCT 
 
GCT GGT ACT GGC AAA TGG 
 
CGGCTACCACATCCAAGGAA 
 
AGC GCC TTC TCG TTA TTC AG 
 
GTG GAC AAC ATC GCT CTG TG 
 
TTC TGA CCA GGT CCA GGA AG 
 
TGC TAC GAC GTG GGC TACG 
 
CAT ATG CCG CAT GAG ACG 
 
CCT GTA TTG TTA TTT TTC GTC ACT ACC T 
 
Egr1, early growth response 1; Bcl2, B-cell CLL/lymphoma 2; Fasn, fatty acid synthase; Tnf alpha, tumor necrosis factor 
alpha, Tnfrsf10b,  tumor necrosis factor receptor superfamily member 10b; 18s, ribosomal subunit.   
Tab 6.1 Sequence of primers used for real-time RT-PCR analyses 
 
 
6.3 RESULTS 
 
The RT-PCR analysis of the total RNA extracted from above-mentioned regions of the 
brain of Wag/Rij rats show that, there is a general tendency to validate the direction and 
magnitude of changes in gene expression indicated by microarray analyses. In table 6.2 
are reported data obtained comparing all epileptic 9 months old rats with all non 
epileptic 4 months old rats (ignoring treatment and region). Moreover, in table 6.3 are 
reported data obtained comparing all Vigabatrin treated rats with all PBS treated rats. 
 
Array Data Real time qPCR
Fold Change ± st err FOLD (2 -∆∆Ct) maen ± st err
Bcl2 B-cell leukemia/lymphoma 2 1,25 ± 0,74 (+25%) 0,70 ± 0,24 (-30%)
Egr1 Early growth response 1 0,85 ± 0,16 (-15%) 0,56 ± 0,23 (-44%)
Fasn Fatty acid synthase 1,08 ± 0,12 (+8%) 1,01 ± 0,21 (+1%)
Tnf Tumor necrosis factor, α 0,26 ± 0,12 (-74%) 0,67 ± 0,17 (-33%)
Tnfrsf10b Tnf receptor superfamily, member 10b 0,49 ± 0,15 (-51%) 0,99 ± 0,28 (-1%)
Gene Symbol Gene Description
 
Tab 6.2 Data from Arraya and qPCR about  the expression of five selected genes comparing all epileptic 9 
months old rats with all non epileptic 4 months old rats. Data are reported as Fold Change mean ± st err.  
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Array Data Real time qPCR
Fold Change ± st err FOLD (2 -∆∆Ct) maen ± st err
Bcl2 B-cell leukemia/lymphoma 2 3,09 ± 2,99 (+309%) 1,37 ± 0,43 (+37%)
Egr1 Early growth response 1 1,16 ± 0,23  (+16%) 1,10 ± 0,56 (+10%)
Fasn Fatty acid synthase 1,29 ± 0,18  (+29%) 1.41 ± 0,42 (+41%)
Tnf Tumor necrosis factor, α 1,71 ± 0,71  (+71%) 1,26 ± 0,47 (+26%)
Tnfrsf10b Tnf receptor superfamily, member 10b 1,86 ± 0,56 (+86%) 1,94 ± 1,01 (+94%)
Gene Symbol Gene Description
 
Tab 6.3 Data from Arraya and qPCR about  the expression of five selected genes comparing all 
Vigabatrin treated rats with all PBS treated  rats. Data are reported as Fold Change mean ± st err.  
 
In order to point out the effect of Age of the animals on the expression of TNFα in any 
one of the specif considered brain region, in Table 6.4 are reported Array and qPCR 
results of expression of this pro-inflamamtoy mediator comparing all epileptic 9 months 
old rats with all non epileptic 4 months old rats.  
 
Array Data Real time qPCR
Fold Change ± st err FOLD (2 -∆∆Ct) maen ± st err
Somatosensory cortex (peri-oral area) 0,21 ± 0,11 (-79%) 0,73 ± 0,11 (-27%)
Visual cortex 0,26 ± 0,25 (-74%) 0,51 ± 0,09 (-49%)
Lateral thalamus 0,10 ± 0,06 (-90%) 0,61 ± 0,23(-39%)
Medial thalamus 0,69 ± 0,49 (-31%) 0,83 ± 0,11 (-17%)
Brain region
 
Tab 6.4 Tnf-α expression from Arrays and qPCR four selected regions of interest comparing all epileptic 
9 months old rats with all non epileptic 4 months old rats. Data are reported as Fold Change mean ± st err. 
 
Moreover, in order to point out the effect of the Vigabatrin treatment on the expression 
of TNFα in in the four selected regions of interest, in Table 6.5 are reported Array and 
qPCR results of expression of this pro-inflamamtoy mediator comparing all Vigabatrin 
treated Wag/Rij rats vs all the PBS treated rats (ignoring age). 
 
Array Data Real time qPCR
Fold Change ± st err FOLD (2 -∆∆Ct) maen ± st err
Somatosensory cortex (peri-oral area) 1,38 ± 0,66 (+38%) 1,22 ± 0,54 (+22%)
Visual cortex 1,71 ± 2,30 (+71%) 1,15  ± 0,50 (+15%)
Lateral thalamus 1,14 ± 0,89 (+14%) 1,46 ± 0,32 (+46%)
Medial thalamus 1,77 ± 0,97 (+77%) 1,19 ± 0,10 (+19%)
Brain region
 
Tab 6.5 Tnf-α expression from Arrays and qPCR four selected regions of interest comparing all 
Vigabatrin treated rats with all PBS treated rats. Data are reported as Fold Change mean ± st err. 
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EXPERIMENT 5: EEG RECORDING AFTER CITOKINES INJECTION 
 
7.1 INTRODUCTION TO EXPERIMENT 5 
 
The role of proinflammatory cytokines on SWDs was recently investigated in WAG/Rij 
rats by the administration of various doses of lipopolysaccarides (LPS) and an increase 
in SWDs was found (Kovacs et al., 2006). However, LPS induces and releases 
numerous proinflammatory mediators, e.g. IL-1β, TNF-α and IL-6. Here we want to 
establish separately the role of IL-1β, TNF-α on seizure activity; we have chosen these 
cytokines since they represent two classes of cytokines that are expressed in the central 
nervous system and are most widely studied in relation with epilepsy (Shandra et al., 
2002; Banks et al., 2001).  
In this experiment was investigated whether these cytokines when added exogenously 
had an effect on SWD‘s. Little is known about the duration, if any, of these effects after 
peripheral administration. Known is that there exists a diurnal rhythm in the expression 
of the effects of IL-1β and TNF-α and that various cytokines may trigger a cascade of 
events also effecting neuronal, endocrinological, behavioural parameters including the 
production of themselves (Rothwell and Hopkins, 1995; Szelényi, 2001). Therefore, the 
expression of SWD following systemic application was investigated for 72 hrs after its 
administration.  
This experiment, as part of a general collaborative agreement, has been performed 
independently by the group coordinated by Prof. G. van Luijtelaar (Radboud 
Nijmegen University, the Netherlands) and has been recently submitted for 
publication (van Luijtelaar et al., submitted).  
 
7.2 MATERIALS AND METHODS 
 
The EEG studies in this experiment were carried out on 32 adult (9 –16 months) male 
WAG/Rij rats, weighing between 266-406 g. Rats lived under standard laboratory 
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conditions, housed in pairs before surgery, food and water ad lib available, room 
temperature was kept at 22-24 °C and a 24 h LD schedule with lights out from 7.00 to 
19.00. After surgery, rats were individually housed in a Plexiglas cage (36*25*15 cm) 
suited for EEG recordings. Procedures involving animals and their care were conducted 
according to University guidelines that comply with international laws and policies 
concerning the use of the laboratory animals in the experimental trials (European 
Community Council Directive 86/609, OJ L 358, I, December 12, 1987). A local ethical 
committee (RU-DEC) approved the protocol.  
Surgical preparation, three standard EEG electrodes (Plastic One, MS303/2) were 
stereotactically implanted under anesthesia with isoflurane (4.5% for induction and 2-
2.5% for maintenance) in oxygen. The EEG-electrode set is fixated with acryl cement 
and two screws, which were placed bilaterally over the cortex. The experiments were 
performed at least 10 days after surgery.  
Experimental protocol, rats were familiarized for 24 hours with the EEG recording 
leads that were connected to a swivel. Signals were amplified and filtered (low pass was 
set at 100 Hz, high pass at 1 Hz).  
The recordings started immediately after the administration of the cytokines or solvent 
at 13.00 and persisted for 72 hrs. The behaviour of the rats was observed every day 
through a window from an adjacent room between 13.30 h till 15.30 h for half an hour 
per rat. Rats were injected i.p. with Interleukine-1β (2μg/kg in 2 ml), TNF-α (2μg/kg in 
2 ml) or a bovine salt solution (0,5 % BSA in PBS)(2μg/kg in 2 ml) as control, group 
size n=9 to 11.  
Analysis of the EEG, The EEG recordings were analysed with a custom made program 
that was previously validated. SWD were initially identified by this program and 
subsequently checked by a trained EEG analyst. Criteria for the detection of SWD can 
be found elsewhere (van Luijtelaar and Coenen, 1986). The cumulative amount of 
SWDs per hour is reported. 
Statistical analysis of the data, the effects of the exogenous administration of cytokines 
on SWD were analysed with a repeated measures ANOVA with cytokine (3 levels) as 
between factor and time as a within subject factor. If necessary, univariate analysis was 
performed followed by Duncan‘s post hoc test (α<0.05). Considering the large number 
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of variables (time points, hours) in relation to the number of animals, it was not possible 
to analyze all the EEG data in one large ANOVA. The effects of the cytokines might 
most likely occur in the first few hours after administration, therefore the first period (1-
6) hours after injection (the dark period) and the remainder of the day, were analyzed 
per hour. The remainder of the recording period was subdivided into days with blocks 
of 2 hours.  
 
7.3 RESULTS 
The number of SWD as recorded over the 72 hr period in the control group is dominated 
by a circadian pattern with a peak in the number of SWDs in the dark period, and a 
smaller number in the light phase of the 24 hour light-dark cycle. A significant time-
effect (p<0.001 and p<0.05 respectively) was found on day 2 and day 3. On both days 
the data could be described with a linear and cubic trend, suggesting that the changes 
over time were not due to chance and showed a maximum and minimum, reflecting the 
circadian distribution of SWDs.  
 
The repeated measures ANOVA for the first 6 hours shows a time effect (p<0.05), a 
treatment effect (p<0.01) and a time x treatment-effect (p<0.05). The interaction 
prompted us to analyze the treatment effects per hour with an univariate analysis 
followed by post-hoc tests. These results are presented in Tab 7.1 
The ANOVA for the first light period (7-18 hr post injection) showed a treatment effect 
(p<0.01). The subsequent post-hoc test showed that the duration of SWD was higher for 
the TNF-α than for the Il-1β and control group. There were no differences between the 2 
groups at day 2 and 3. 
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Fig.7.1  Mean and St. errM of the total duration of SWD per hour as a function of time after injection of 
bovine, TNF-α and IL-1β. Note the immediate increase after IL-1β injection and the delayed increase of 
TNF-α  in the subsequent light period (7-18 hrs after injection). D=dark period, L=light period. *; 
significative differently of IL-1β Vs Bovine (p<0,05), #; significative differently of TNF-α Vs Bovine 
(p<0,05) 
 
  
Hours F-value P value Post-hoc 
0-1 4.26 0.021 IL > Bov 
1-2 5.14 0.011 IL > Bov, TNF 
2-3 3.64 0.044 IL > Bov, TNF 
3-4 4.12 0.024 IL > Bov, TNF 
4-5 8.63 0.001 IL > Bov, TNF 
5-6 2.26 n.s.  
 
Tab 7.1 Inferential statistics concerning the first 6 hours of the total duration of spike-wave discharges 
after injection of bovine, Il-1ß (Il) and TNF-α (TNF). The post-hoc tests revealed that IL-1β enhanced 
SWDs expression 1-5 hrs after its administration. 
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EXPERIMENT 6: CITOKINES CONCENTRATION IN BRAIN AND PLASMA 
8.1 INTRODUCTION TO EXPERIMENT 6 
In this experiment we established the role of these two cytokines in the pathogenesis of 
absence epilepsy by measuring their levels in brain and plasma at an age of 2, 4 and 6 
months of age. Since cytokines are active during neural development as well as in the 
adult nervous system, both during normal function and in pathological conditions their 
role in causing SWD cannot be excluded at forehand. 
This experiment, as part of a general collaborative agreement, has been performed 
independently by the group coordinated by Prof. G. van Luijtelaar (Radboud 
Nijmegen University, the Netherlands) and has been recently submitted for 
publication (van Luijtelaar et al., submitted). 
 
8.2 MATERIALS AND METHODS 
ELISA methods, 51 rats (25 ACI and 26 WAG/Rij) experimentally naïve were used in 
the ELISA study. Rats were 2, 4 and 6 months old.  All rats were killed by decapitation 
and their brains were rapidly removed at 4
o 
C and frozen on dry ice. Brain tissue was 
weighted and homogenized in ice-cold PBS (5 gm/ml) using a Potter homogenizer 
(1000 rpm, 10 strokes). The homogenates were centrifuged for 10 min (5000 rpm, 4
o 
C). 
One hundred microliters of the supernatant were taken in duplicate to measure TNF-α 
and IL-1 content. TNF-α and IL-1 were determined using selective antibodies 
(―Biotrak‖ system from Amersham Pharmacia Biotech, USA). Absorbance was read at 
405 nm. The detection limit was 4.0 pg/ml. The data are expressed in pg/mg of wet 
brain tissue. For each determination 0,416 mg of tissue was used in 50 mcl of 
investigated solution for IL-1 and ten times less- for TNF-α. 
Statistical analysis of the data, the outcomes of the ELISA method were determined 
with MANOVA with strain (2 levels), age (3 levels) and operation (yes/no) as between 
subject variables. Since there were no main effects of operation nor interactions with 
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operations, the data were pooled in a final two way MANOVA, followed by univariate 
ANOVA‘s and post-hoc tests.  
The number of SWDs as measured in the comparative study between 2 and 6 month 
WAG/Rij and ACI rats were analysed with ANOVA with strain and age as between 
group factors. Statistical analysis was done with SPSS version 10.0 for Windows. 
Graphics were made with Prism 3.0. 
 
8.3 RESULTS 
The data of the immunological investigations are presented in Tab 8.1. The overall 
ANOVA showed a strain x age effect (p<0.05). Univariate tests showed significant 
strain effect for TNFα serum levels (p<0.05; WAG/Rij > ACI) and an interaction 
between strain and age (p<0.01) and a similar interaction for TNFα in the brain 
(p<0.01). Subsequent post-hoc tests showed that plasma levels were higher in 2 months 
WAG/Rij vs age matched ACI‘s rats, and brain concentrations tented to be higher in 4 
months old WAG/Rij rats (p<0.01). There were no differences in 6 months old rats. 
Strain Indices under Age of animals in months, (number of rats) 
 Investigation 2 4 6 
 TNF-α, serum 6,31 + 2,0** 
(n=12) 
2,47 +  0,89 
(n=13) 
1,84 + 0,94 
(n=12) 
WAG/Rij TNF-α, brain 63,8 + 2,6 
(n=11) 
78,7 + 8,4* 
(n=11) 
67,3 + 3,2 
(n=12) 
 IL-1β, serum 1,59 + 0,78 
(n=12) 
2,58 + 0,74 
(n=12) 
1,04 +  0,53 
(n=12) 
 IL-1β, brain 27,0 + 2,8 
(n=11) 
32,5 + 3,8 
(n=11) 
25,8 + 1,7 
(n=11) 
 TNF-α, serum 0,61 + 0,34 
(n=12) 
3,53 + 1,50 
(n=12) 
1,27 + 0,53 
(n=13) 
ACI TNF-α, brain 70,3 + 3,3 
(n=11) 
62,2 + 4,2 
(n=11) 
62,3 + 2,6 
(n=11) 
 IL-1β, serum 1,79 + 0,78 
(n=12) 
1,96 + 1,07 
(n=12) 
1,54 + 0,73 
(n=12) 
 IL-1β, brain 30,9 + 2,8 
(n=11) 
31,7 + 2,7 
(n=10) 
29,2 + 1,8 
(n=12) 
 
Tab. 8.1 Mean and SEM of TNF- and IL-1 (pg/mg of wet brain tissue) content in serum and brain 
tissue of WAG/Rij and ACI rats at 2, 4 and 6 months of age; ** = p<0.05; * = p<0.01 - Significantly 
different from age matched ACI group. Two factor (Age and strain) ANOVA followed by post-hoc tests 
were used.  
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GENERAL DISCUSSION 
 
Four leading theories endeavor to explain the origin of the generalized spike-wave 
discharges associated with absence seizures.  1) Penfield and Jasper (1954) put forward 
the ―centrencephalic‖ theory, proposing that spike-wave discharges originate from a 
deeply located, subcortical pacemaker in upper brainstem and midline thalamus, this 
pacemaker having wide-spread projections to both sides of the cortex. 2) Buzsáki et al. 
(1988) proposed the ―thalamic clock‖ theory, in which the reticular thalamic nucleus 
contains the pacemaker cells for the spike-wave discharges. It must be stressed that in 
these theories the cortex has only a passive function. 3) On the other hand, the ―cortical‖ 
theory of Bancaud (1972) and Niedermeyer (1972) implies that the generalized spike-
wave discharges originate from a focus, or foci, in the cortex. In this theory, subcortical 
structures are not essential for the generation of spike-wave discharges but only 
participate passively. 4) The ‗corticoreticular‘ theory postulated by Gloor (1968, 1969) 
forms a bridge between the thalamic and cortical theories, implying that a 
hyperexcitable cortex  responds abnormally to initially normal, thalamocortical volleys, 
thereby initiating, in such a way, abnormal thalamocortical oscillations. Thus, in all four 
views, a prerequisite for the occurrence of spike-wave discharges is a highly 
synchronized activity of thalamocortical or corticothalamic connections. The 
widespread, bilaterally synchronous spike-wave discharges are reflections of highly 
synchronized oscillations in thalamo–cortical–thalamic networks. Moreover, it now 
seems quite clear that the reticular thalamic nucleus is the driving force behind the 
generation of sleep spindles. Recently, Meeren et al. (2002) extensively studied the 
initiation and generalization of spike-wave discharges by describing the 
interrelationships between multisite cortical and thalamic field potentials recorded in 
freely moving WAG/Rij rats. Nonlinear association analysis revealed a consistent 
cortical ―focus‖ within the perioral region of the somatosensory cortex. The spike-wave 
discharges recorded at other cortical sites consistently lagged behind this focal site, with 
time delays that increased with electrode distance. Intrathalamic relationships were 
more complex and could not account for the observed cortical propagation pattern. 
Cortical and thalamic sites interacted bidirectionally, whereas the direction of this 
coupling could vary throughout one seizure. However, during the first 500 ms, the 
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cortical focus was consistently found to precede the thalamus. These findings argue 
against the existence of one common subcortical pacemaker for the generation of 
generalized spike-wave discharges characteristic for absence seizures in the rat. Instead, 
the results suggest that a cortical focus is the dominant factor in initiating the 
paroxysmal oscillation within the corticothalamic loops, and that the large-scale 
synchronization is mediated by way of an extremely fast intracortical spread of seizure 
activity (Meeren et al., 2002). During the first cycles of a seizure the cortex drives the 
thalamus, which subsequently becomes entrained into the oscillation, thus maintaining 
the discharges. Once the oscillation has been set into motion, cortex and thalamus act as 
a unified oscillatory network. In brief, the cortex triggers the thalamus and the intact 
thalamus maintains the sustaining character of the discharge. The outcomes of the 
Meeren et al. (2002) studies provide evidence to formulate the hypothesis of a cortical 
focus that comprehensively drives corticothalamic networks during the occurrence of 
spontaneous spike-wave discharges in rats. Rather than being an aberrant form of 
spindle oscillations originating from the thalamus, spike-wave discharges appear to be a 
phenomenon that shares the general ―focus-propagation-generalization‖ principle of 
cortical seizures. Moreover, independent component analyses of multisite cortical EEG 
recordings in absence epileptic patients have shown an early independent component in 
the frontal EEG (McKeown et al., 1999). Hence, the findings of Meeren et al. (2002), as 
well as those of McKeown et al. (1999), strongly challenge the concept of the 
―centrencephalic‖ theory of generalized absence epilepsy, but form, instead, a synthesis 
between the ―cortical‖ and the ―corticoreticular‖ theories. This ―cortical-driven and 
thalamic-sustained‖ theory of the origin of spike-wave discharges, as proposed by 
Meeren et al. (2002), provides a new and interesting concept. 
In order to raise the evidence of a focal cortical theory for absence epilepsy, we studied 
whether structural and functional damage or differences occurs in cerebral areas which 
are known more involved in absence epilepsy.  
 
DWI alterations reflect pathological conditions in brain tissue that are only partially 
understood, and involve changes in the diffusion characteristics of intra- and 
extracellular water compartments, and water exchange across permeable boundaries 
(Gass et al., 2001). In general, alterations associated with acute vasogenic edema or 
tissue destruction usually show elevations of the DWI, while a reduction of the DWI has 
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been associated with acute cytotoxic edema (Gass et al., 2001). This may explain the 
present findings of decreased DWI value in the cortex of older rats if compare to 
younger ones, and the general lower DWI value after Vigabatrin treatment. Data 
observed in sub-cortical regions shows that DWI signal for lateral Thalamus is the 
lowest if compare to Hippocampus and medial Thalamus results.  
Result of structural MRI analysis reveal an age dependent decrease of T2 values in 
somatosensory cortex (both supra- and sub-granula layer) and lateral thalamus, 3 
regions involved in absence seizures. The decrease in T2 might indicate a decline in 
extracellular water. As alternative explanation, some authors suggest that an increased 
concentration of paramagnetic deoxyhemoglobin causes a decrease in T2 (Lei et al., 
2003). This so-called negative BOLD effect has been shown to occur in MR studies of 
hypoxic hypoxia in the rat. Deoxyhemoglobin increases in situations in which the 
metabolic requirement for oxygen is not met by the delivery of oxygen.  
 
Result of functional MRI reveal a general cortical decrease of rCBV after Vigabatrin 
treatment. Moreover, referred to subcortical data, lateral thalamus have the lowest value 
of rCBV. A reduction in rCBV might be a consequence of edema, resulting from 
imbalance of water distribution, vascular alteration or perivascular inflammation, which 
causes vessel compression (Nawashiro et al., 1994). 
Our data indicates an increase of rCBF in all the cortical and subcortical regions in 
oldest epileptic animals. The increase in rCBF was hypothesized to be primarily 
because of increased glucose metabolism, resulting from increased inflammatory cell 
activation (Juhler and Paulson, 1986). 
 
Gene array and real time RT-PCR data and Elisa analysis demonstrate a general age-
related down-regulation of Tnf-α in all the four cerebral areas considered in our studies, 
so a general tone decrease of this mediator in the brain of epileptic animals could be 
present. 
Regarding real time RT-PCR, data related to the expression of Tnf-α are very 
interesting. Results seem to attest that somatosensory cortex and visual cortex are 
involved in different way. Results point out a minor age-related down-regulation of Tnf-
α in the peri-oral area than in the visual cortex. The same gene is also more up-regulated 
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in the somatosensory cortex and in lateral thalamus than in the other two brain regions 
after Vigabatrin treatment (which results in a increase of seizures).  
It is important to note the up regulation of IL1α in the oldest epileptic Wag/Rij rats and 
also after vigabatrin treatment. IL-1α, IL-1β, together with IL-1 Receptor antagonist 
(IL-1RA) are mebers of IL1 superfamily. For the most part, IL-1α, IL-1β bind to the 
same cellular receptor. This receptor is composed of two related, but non-identical, 
subunits that transmit intracellular signals via a pathway that is mostly shared with 
certain other receptors. IL1α and IL-1β and also Tnf- α  signals are amediated by NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) patway. In particular, 
Tnf-α and IL-1β dose-dependently inhibited astrocyte glutamate uptake (Hu et al., 2000; 
Danbolt, 2001). NF-κB is a protein complex that controls the transcription of DNA and 
is found in almost all animal cell types and is involved in cellular responses to stimuli 
such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and 
bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to 
infection. Conversely, incorrect regulation of NF-κB has been linked to cancer, 
inflammatory and autoimmune diseases, septic shock, viral infection, and improper 
immune development. NF-κB has also been implicated in processes of synaptic 
plasticity and memory and data presented in this study seems to demonstrate that it‘s the 
most involved signal-transduction patway in Wag/Rij animal model of absence 
epilepsy.   
One of the main goals of this study was to establish a relationship between the cytokine 
IL-1β and TNF-α and absence epilepsy. We choose the WAG/Rij model for that 
purpose. The outcomes of the experiment 5, in which TNF-α and IL-1β were 
administered i.p. and the effects on SWD were determined in a 72 hour period, show an 
immediate and short lasting increase on SWD of IL-1β and a delayed increase in SWD 
after TNF-α. The intraperitoneal route of IL-1β and TNF-α administration was chosen 
since it has been established that cytokines reach the CNS directly by crossing at leaky 
areas the BBB through the circumventricular organs even in healthy, basal conditions 
(Shandra et al., 2002; Banks et al., 2001). In agreement with data as obtained in models 
of focal onset, fever or infection related (Vezzani and Granata, 2005) and in the same 
genetic model after the administration of LPS (Kovacs et al., 2006), IL-1β aggravated 
absence seizures. The present outcomes demonstrate also that the acute effects, as found 
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after bacterial LPS were not due to TNF-α, but to either IL-1β or to other non-tested 
cytokines.   
The effects of IL-1β on the cumulative duration of SWD occurred rather quickly, in the 
first few hours after its peripheral administration. Its fast onset suggests a direct effect, 
while the effects after LPS occurred after 90 till 270 min. It is known that IL-1β induces 
its own synthesis and the synthesis of IL-6 and TNF-α in the central nervous system, 
mainly in astrocytes and microglia (Vezzani et al., 1999). It is not known whether IL-6 
modulates SWD, however, TNF-α had only a delayed effect, the increase of SWD 
occurred only after 7-18 hours after the administration. Interestingly, LPS has time 
dependent effects on the production of TNF-α: its reaches a peak concentration 6h post 
treatment in a rat glial cell culture (Shemi et al., 2000). Since a direct effect on SWDs is 
not taking place after TNF-α, another physiological or hormonal mechanism might be at 
work here. Interestingly, the bioavailability and gene expression of TNF-α has a 
circadian rhythm with peak levels at the beginning of the light period (Krueger et al., 
1998). At specifically these hours of the 24 h light dark cycle, the number of SWD is 
usually quite low (van Luijtelaar and Coenen, 1988; van Luijtelaar et al., 2001). These 
two facts suggest an inverse relationship between SWD and TNF-α levels. We consider 
this as another argument for our suggestion that it is not TNF-α itself that is responsible 
for the increase but another factor, perhaps IL-1β itself since this interleukin has SWD 
enhancing effects. We propose that the effects of TNF-α on SWDs are not mediated by 
TNF-α, but by another unknown factor. 
The mechanisms through which the cytokines affect SWD activity by interfering with 
neurotransmitters of hormones in rats are multiple. The action of IL-1β may involve an 
increase in or facilitation of glutamatergic function through NMDA receptors. 
Activation of glutamate receptors of the NMDA subtype leads to an increase in 
depolarisation and burst firing of neurons. It is known that various types of NMDA 
agonists enhance SWD (Peeters et al., 1990). IL-1β may also directly enhance NMDA 
receptor function, because IL-1β receptors are associated with signal transduction 
pathways known to affect the response of NMDA receptors to endogenous ligands 
(Vezzani et al., 1999). The NMDA receptor requires both binding of glutamate and 
depolarization to allow entry of Ca
2+
 into the cell. The pattern of excitation/inhibition 
provokes a massive calcium entry that specifically activates Ca
2+
 dependent molecular 
90 
 
gates in thalamo-cortical cells involved in burst firing characterizing SWD (Sejnowski 
and Destexhe, 2000). Depolarizing pulses of Ca
2+
 that enter the thalamic and cortical 
neurons may influence membrane excitability and enzyme cascades. So, IL-1β may 
have an effect on Ca
2+
 increase in bursting cells by mediating their NMDA receptors. 
Ca
2+
 would then be available in the cell for the generation of bursting patterns and 
perhaps for protein synthesis. 
The delayed effects of TNF-α might be also be explained by the inhibitory effect of 
TNF-α on glutamate uptake (Pickering et al., 2005). A decrease in glutamate uptake 
increased extracellular glutamate level, which in turn resulted in glutamate-induced cell 
swelling; brain edema occurs commonly in epilepsy (Chang et al., 2001). Glutamate 
cannot enter the cell as long as TNF-α has its inhibiting effect. Brain tissue is known to 
have a remarkable ability to store glutamate (Danbolt, 2001). The only way this 
glutamate will be removed is through the working of transporter proteins, which provide 
glutamate to the cell for synthesis of e.g. GABA and energy production. The 
concentration transporter proteins will be at a relatively low level in contrast with the 
sudden enormous increase of extracellular glutamate after TNF-α injection. The TNF-α 
effect has worn out, after approximately 5-6 hours, just like IL-1β, while the 
concentration transporter proteins has increased because of the high abundance of 
glutamate. Now the accumulated glutamate massively enters the cell and has a 
positively effect on the occurrence of SWD on a cortical level. This hypothesis is 
feasible considering than NMDA aggravates SWD in WAG/Rij rats (Peeters et al., 
1990; Filakovszky et al., 1999). This effect may last about 12 hours until the 
concentration glutamate transporters will return to basal levels.  
It is also quite well possible that the presently found increase in SWDs is due to non-
specific effects induced by the cytokines. Beside their well-known actions including 
effects on the HPA axis, fever responses, and somnogenic effects. Some of these factors 
have well described effects on the occurrence of SWDs.  Corticosteroids and stress 
facilitate the occurrence of SWD (Schridde and van Luijtelaar, 2004; Tolmacheva and 
van Luijtelaar, 2006), while corticosteroids also induce β-endorphin release. β-
endorphin is known to enhance the mu- and delta-opioid receptors, the mu-opioid 
receptor agonist DAMGO increased SWD in WAG/Rij rats (Przewlocka et al., 1998). 
Larger concentrations of TNF-α were found in plasma of WAG/Rij vs ACI rats 
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(irrespective of age), next to an age-dependent strain differences. The serum level of 
TNF-α was enhanced in young WAG/Rij rats preceding the onset of SWDs, the brain 
concentration tended to be increased in WAG/Rij rats when rats were 4 months of age. 
When SWD were fully developed at 6 months of age, there were no longer differences 
between the two strains. Therefore, in all, there is some evidence that TNF-α might be 
involved in the pathogenesis of absence seizures in WAG/Rij rats, IL-1β not. This 
cytokine plays a crucial role in more dramatic forms of epilepsy such as status epilepsy, 
or kindling. The strain difference, the large concentration of TNF-α in pre-epileptic rats 
and the somewhat increased brain concentrations in 4 months old rats might be 
considered as a form of neuroprotection towards the changes from a pro-epileptic to an 
epileptoformic brain. Neuroprotective effects for cytokines have been proposed e.g. by 
Peltola et al. (1998). Plata Salaman (2000) proposed that cytokines play a role in 
adaptive mechanisms associated with generalized seizure activity with implications for 
neuroprotection.  
Age
Increased extracellular glutamate level 
Higher concentration of TNF-α
in SS cortex than in Visual cortex
(in spite of a general reduction of tonic
concentration of TNF-α)
Inhibitory effect on astrocyte 
glutamate uptake
(NFkB mediated)
rCBF and 
rCBV
perturbation
Facilitation of glutamatergic function
through NMDAreceptors
Positively effect on the 
occurrence of SWDs
Vigabatrin treatment
Increase Tnf-α concentration
Acute Tnf-α injection
Why?
T2 and DWI perturbation Brain Inflammation
Acute Il1-β injection
Concentration of 
transporter proteins of 
Glutamate has increased
Increase Il1-β concentration
 
Fig. 9.1 Schematic representation of possible pathways involved in the aetiopathogenesis of absence 
epilepsy, as deduced by the data reported in the present thesis. In particular, the possible neuromodulator 
role of inflammatory players like IL-1B and TNF-a are discussed. Many questions need still to be 
answered; for example, how Vigabatrin treatment induces a TNF-a increase. Further experiments have 
been planned and are currently ongoing in our laboratory. 
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